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Abstract 
/S -hemoglobinopathies are the most commonly inherited blood disorder in the 
world and caused by a number of genetic defects in ^ -globin gene resulting in the 
reduced /3 -hemoglobin synthesis or production of abnormal fi -hemoglobin. 
In /3 -thalassemia, deficient yS -globin production causes an imbalance in the 
a / / 3 -chain ratio and excess a -chains precipitate within the red blood cell resulting 
in hemolysis. The phenotypic presentation of yS -thalassemia varies, depending on the 
degree of a!^ imbalance. Two forms of severe -thalassemia can be identified, 
the major and intermedia. Patients with fi -thalassemia major require blood 
transfusion to sustain lives as they are depleted of functional adult hemoglobins. In 
/3 -thalassemia, a significant increase in y -globin production can partially replace 
the defective /5 -globin, thus preventing precipitation of unpaired a -globin chains. 
Therefore, reactivation of a -globin gene expression sheds light on ameliorating P 
-thalassemia symptoms. Hydroxyurea is the only drug in clinical use for treatment of 
13 -thalassemia by stimulating 7 -globin gene expression. Unfortunately, 
administration of hydroxyurea suffers numerous drawbacks such as lack of potency, 
myelosuppression and short half-life. Yet lots of compounds have been identified to 
induce fetal hemoglobin production in human erythroleukemia cell line K562 but still 
pending on clinical trials. A lead compound LC978 purified from Chinese herb is 
found to be 2000-fold more potent than hydroxyurea in elevating fetal hemoglobin 
production and of much lower toxicity. 
The signal transduction pathways modulated by LC978 in K562 was studied 
with the use of oligo Human Signal Transduction PathwayFinder microarray and the 
mitogen-activated protein Wnase (MAPK) pathways were found to be major 
responder to LC978. These microarray data were verified by real-time RT-PCR. The 
roles of three major MAP kinases - ERK, JNK and p38, were evaluated by cell-based 
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phosphorylation ELISA to monitor the phosphorylation level of these kinases. Results 
showed that phosphorylation levels of ERK and JNK were unaffected while there was 
a prominent increase in phosphorylated p38 upon LC978 addition. To test whether 
p38 did involve in regulating 7 -globin gene expression, cells were treated with 
specific p38 inhibitor SB203580 and fetal hemoglobin (HbF) production was 
measured by human HbF ELISA. The treatment with SB203580 resulted in the 
inhibition of HbF induction by LC978 by about 2.8 folds. 
Through our understandings on the signaling cascade modulating 7 -globin 





-球蛋白鏈基因的遺傳缺損而弓丨起，有缺陷的e -球蛋白鏈基因會導致13 -球蛋白鏈 
的製造減少或產生不正常的/3-球蛋白鏈。 
球蛋白鏈的製造不足會引致a -和yS-球蛋白鏈比例不平衡，過量的a -球 
蛋白鏈會沉殿於紅血球細胞內令紅血球溶解。地中海貧血的表現型態是取決 













寡核苷醱信號轉導通路發現者基因芯片（ o l i g o Human Signal Transduction 
PathwayFinder microarray)去飄別主要的信號機制，結果發現LC978主要是透過 
有絲分裂原活化蛋白激酶 (MAPK)去誘導胎兒血紅蛋白的生產；此實驗結果再 
以實時逆轉錄-聚合酶鏈鎖反應（Real time RT-PCR)加以證實。然後’通過細胞 
活化信號酶聯免疫吸附分析（cell-based phosphorylation ELISA) ’我們量度了 
M A P K家族成員中的細胞外信號調控激酶（E R K ) � c - j u n氨基端激酶（ J N K )和 
p 3 8應激活性蛋白激酶 ( p 3 8 )的硫酸化的程度，結果發現在L C 9 7 8誘導下，細 
XV 
胞的E R K和 J N K的磷酸化程度沒有改變；但是 p 3 8的的碟酸化程度明顯增 
加。我們再進一步求證p38和調控胎兒血紅蛋白產生的關係，細胞先以蛋白激酶 
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Chapter 1 General Introduction 
1.1 Hemoglobin - Structures, Types and Functions 
1.1.1 Structures of Hemoglobin 
In blood, hemoglobin (Hb) is present in red blood cells and functions as 
oxygen-transporting protein. It transports oxygen from lungs to other parts of the body. 
The name hemoglobin is the concatenation of heme and globin. Each globin interacts 
with a prosthetic group called heme, and each heme group is able to bind with an iron 
atom. This structure is then responsible for the binding of oxygen. 
Hemoglobin is a tetrameric macromolecule which consists of an assembly of 
four globular protein subunits. The polypeptides are made up of a -helical segments. 
These four subunits are composed of two identical a -chains and two identical j3 
-chains. The a - and (3 -chains are bonded non-covalently and they are held in 
position by means of hydrogen bonds, salt bridges and hydrophobic interactions. 
Though the two types of chains do not share similar amino acid sequence, their 
three-dimensional structures are similar (Nelson and Cox, 2000). 
The heme group consists of a complex organic ring structure, porphyrin, to 
I 
which a single iron atom in its ferrous (Fe ) state is bound (Figure 1-1). The iron 
atom is bonded to four nitrogen atoms that are part of the porphyrin ring system. 
There are two additional bonds to Fe^^ perpendicular to the porphyrin. One of these 
two bonds is connected to the globin chain and the other is the binding site for oxygen. 
The iron atom in its ferrous state can bind oxygen reversibly; while the ability to bind 
oxygen is lost when the iron is in ferric (Fe^^) (Nelson and Cox, 2000). 
1 
广 CH, 
HC, Fe V h 
> / M 
丨—C COOH 
Figure 1-1. Structure of a heme molecule. 
1.1.2 Types of Hemoglobin 
Erythrocytes are cells producing hemoglobin. At different developmental stages, 
the sites of blood cell formation (hematopoiesis) and hence the synthesis of 
hemoglobin shifts accordingly. This change is tightly regulated such that the globin 
genes are expressed in the order that they are arranged on chromosome 16 and 11 
respectively (details will be discussed in the later section). 
During the embryonic stage, hematopoiesis takes place in the yolk sac and 
Gower 1 ( ( 2 e 2), Portland (12 7 2) and Gower 2 ( a 2 £ 2) dominate. During the fetal 
stage, liver, spleen and bone marrow are responsible for hematopoiesis and the 
predominant form of hemoglobin is the fetal hemoglobin (HbF) (Q： 2 7 2). HbF persists 
as the major form of oxygen carrier until three to six months after birth where adult 
hemoglobin (HbA) (a 2 ^2) accounts for 96-98% of total hemoglobin found in blood. 
The remaining hemoglobin is comprised of HbA2 {aid2) and HbF. The synthesis of 
6 -chain starts late in the third trimester and persists in adults and has a normal level 
of 1.5-3.2%. However, HbF synthesis is restricted to a group of red blood cells called 
F cells. .The level of HbF in adult blood is very low, only accounts for 0.5-0.8% 
(Hoffbrand et al., 2001). The whole developmental regulation of human hemoglobin 
is depicted in Figure 1-2. 
2 
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Figure 1-2. Spatial and temporal regulation of human hemoglobin synthesis. 
1.1.3 Functions of Hemoglobin 
The red blood cells in systemic arterial blood carrying oxygen from the lungs to 
the tissues and return in venous blood with carbon dioxide to the lungs. The ability of 
a hemoglobin molecule to load and unload oxygen is facilitated by the movements of 
the globin chains. The contacts between a\/3\ and a i /S i stabilize the hemoglobin 
molecule. During oxygenation and deoxygenation, the /3 -chains slide on the a i /3 2 
and a 2 yS 1 contacts (Nelson and Cox, 2000). 
There are two major conformations of hemoglobin that facilitate loading and 
unloading of oxygen - the T and R states. The binding of oxygen to a T-state 
hemoglobin triggers a change in conformation to the R-state which allows the heme 
group to adapt to a more planar conformation. This change results in the shifting of 
the position of histidine residue bound to the iron atom and the a -helix. The 
structural rearrangements within the hemoglobin molecule enable the cooperative 
binding of oxygen (Chakalova et al.’ 1974; Nelson and Cox, 2000). 
The cooperative binding of oxygen - the binding of oxygen to one of the 
subunits of the hemoglobin molecule induces a conformation change in the whole 
complex causing other subunits to take up oxygen. Thus, the oxygen dissociation 
3 
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Figure 1-3. The oxygen dissociation curve. 
The affinity for oxygen of hemoglobin is affected by the concentration of protons 
and carbon dioxide. Protons bind at various places along the protein and carbon 
dioxide binds at the a -amino group forming carbamate. These two factors act to 
reduce the oxygen affinity. The regulation of oxygen binding by hydrogen ions and 
carbon dioxide is called the Bohr Effect. Because of such effect, oxygen unloading is 
favored in tissues where there is high concentration of respiratory product, carbon 
dioxide. High oxygen affinity is resumed in lung when carbon dioxide and hydrogen 
ions are released there (Chakalova et aL, 1974). 
However, carbon monoxide does not regulate oxygen binding as that by carbon 
dioxide. Carbon monoxide competes with oxygen for the same binding site, and 
hemoglobin has a much higher affinity for carbon monoxide. Once carbon monoxide 
binds with hemoglobin, bright red carboxyhemoglobin will be formed (Berg et al.’ 
2002). 
Apart from carbon dioxide and hydrogen ions, 2,3-bisphosphoglycerate 
(2,3-BPG) also regulates oxygen affinity. It preferentially binds to deoxyhemoglobin 
and stabilizes the molecules and hence reduces oxygen affinity. Regulation of oxygen 
affinity by 2,3-BPG has an important role in fetal development. The 2,3-BPG binding 
4 
site of the 7 -chain has been substituted with a histidine residue at position 143 
which remove two positive charges from the binding site. Therefore, HbF has a lower 
affinity for 2,3-BPG while an increased affinity for oxygen and this allows the fetus to 
obtain oxygen from maternal blood (Berg et al., 2002). 
1.2 Human Globin Genes and Their Regulation 
1.2.1 Organization of the Human Globin Genes 
In human, two gene clusters direct the synthesis of hemoglobin during 
development. The a -locus is located on the short arm of chromosome 16 with seven 
genes organized in the order: 5'- f -v f i-\|/a2-\|/ai-a2-ai- 0 -3', where \\f denotes 
pseudogenes (Figure 1-4). How the presence of these pseudogenes and the expression 
of 6 -gene regulate or affect the expression of the embryonic and adult alpha genes is 
still a stumper (Tang et al,, 2006). 
HS40HS33 HS10HS8 HS4 0 CL1 a 2 C 
5 u u I n n _ _ • _ _ a _ 3 ’ 
Figure 1 -4. Organization of the a -globin gene cluster. 
The human /3 -globin gene cluster reside on the short arm of chromosome 11 
and five functional genes are arranged in the order in which they are expressed during 
ontogeny of erythroid cells: 5'- £ 7 7 - (5 - /3 -3'. These genes are exclusively 
expressed in erythroid tissues and regulated in a developmental stage specific manner. 
The e -gene is expressed first in the embryonic yolk sac followed by a gradual switch 
to the expression of the 7 genes which predominates during the fetal liver stage. There 
are two 7 -genes, ° 7 and 八 j , which differ at the amino acid at position 136, one 
codes for glycine and the other for alanine (Figure 1-5). In the late fetal liver and 
neonatal stages, there is a second transition to the expression of the -gene and the 7 
-gene is almost completely silenced during adult life (Provan and Gribben, 2000). 
5 
HS 5 4 3 2 1 £ ^ r (5 B 3，HS 
3 , 丨 i i i i n n n n n n I 3. 
Figure 1-5. Organization of the ^ -globin gene cluster. 
Each globin gene has three exons and two intervening sequence (IVS) in 
between them. The IVS will be spliced out after transcription leaving the mature RNA 
with three exons joining together to be translated to give a functional hemoglobin 
chain (Provan and Gribben, 2000). 
1.2.2 Regulation of Globin Gene Expression 
1.2.2.1 The Locus Control Region (LCR) 
The developmental control of globin genes is accomplished through complex 
interaction between the globin genes and a number of regulatory elements. One of the 
major elements involved is the LCR. 
On the /3 -globin gene cluster, the LCR is placed at 6 to 22kb upstream of the 
5' end of the e -globin gene. The LCR spans about 16kb and contains five DNAse I 
hypersensitive sites (HSs). The DNAse I HSs of the LCR contain core elements which 
are 200-3OObp long. These sites have sequences for binding with various 
erythroid-specific and constitutive transcriptional factors. Among the five HSs, HS2 is 
found to have classical enhancer activity (Jia et al, 2003; Jackson et al., 2003) while 
HS3 and HS4 (Bungert et al., 1995; Navas et al, 2001; Jackson et al, 2003) are able 
to activate transcription via interaction with other chromatin domains. HS5 acts as an 
insulator (Li and Stamatoyannopoulos, 1994; Tanimoto et al., 2003; Wai et al, 2003). 
However, the function of HSl is still under investigation (Fraser et al, 1990). 
In addition to the globin gene promoters, there is an HS located at the 3’ of the 
-globin gene cluster. This 3' HSl is specific to erythroid cells and may also play a 
role in stabilizing the interaction between the globin gene and the LCR (Fleenor and 
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Kaufman, 1993). The LCR may interact with specific transcriptional factors and 
globin gene promoter to activate the transcription process. 
There are also five HSs upstream the a -globin gene cluster, they are the HS4, 
HS8, HSIO, HS33 and HS40 (Tang et a/., 2006). HS40 behaves as an enhancer (Chen 
et al., 1997; Zhang et al., 2002) while the functions of the remaining HSs are largely 
unknown. 
1.2.2.2 Cw-Regulatory Elements 
Besides the LCR, there are other cw-acting elements involved in regulating the 
temporal expression of globin genes. These include promoters, enhancers and 
silencers. 
1.2.2.2.1 Promoters 
Each globin gene is accompanied by its promoter placed upstream of the coding 
region to recruit the RNA polymerase to initiate transcription. There are unique 
sequences in the promoter region where specific DNA-binding proteins can fit the site, 
and the DNA-protein complex will recruit the RNA polymerase to turn on 
transcription. 
The promoters of all globin genes share significant homology but they also have 
unique sequences that are responsible for binding developmental-stage specific 
transcriptional factors. There are three major conserved regulatory elements: the 
TATA, CCAAT and CACCC or GGGGTG boxes (Myers et al, 1986). Each globin 
gene promoter has single or duplication of these boxes. For example, the y -globin 
gene promoter contains two CCAAT-boxes. Though each globin gene has similar 
promoter elements, their activity is tightly regulated by the stage-specific transcription 
factors (Harju et al., 2002). 
1.2.2.2.2 Enhancers 
Enhancers are DNA sequences that increase the transcription from a promoter in 
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a position-independent manner. As discussed in Section 1.2.2.1, the HS2 on the (3 
-globin gene cluster and HS40 on the a -globin gene cluster are examples of 
enhancer elements. Two pieces of enhancer elements have been identified, one is 
located at approximately 400 base pairs 3 ’ to the polyadenylation signal of t h e � y 
-gene (Bodine and Ley, 1987) and the other is at the 3，of the jS -globin gene (Buzina 
et (7/., 2005). 
1.2.2.2.3 Silencers 
Silencers are DNA sequences that bind repressor protein to interfere with the 
transcription and cause downregulation of gene expression. At the 5’ boundary area of 
HS5, a tandem repeat of seven GATA sequences acts as a proximal repressor of HS2 
enhancer activity (Ramchandran et al, 2000). There is a silencer at the distal 
promoter of the s -globin gene which facilitates autonomous silencing during 
development. The CCAAT-box region of e -gene promoter contains two direct repeats 
(DR) sequences which bind a novel protein called direct repeat erythroid-defmitive 
binding protein (DRED) (Filipe et al, 1999). The binding of DRED to the 
CCAAT-box region interferes the interaction of erythroid Kriippel-like factor (EKLF) 
with that region. A DR element is also found in y -globin gene promoter (Omori et 
al., 2005) which facilitates silencing in a manner similar to that involved in e -globin 
gene silencing. Two silencers have been located 5' of the /5 -globin gene which bind 
repressor protein BPl and BP2 (Berg et al, 1989; Ebb et al, 1998). 
1.2.2.3 Tra/is-Acting Factors 
Developmental stage specific and ubiquitous transcription factors form an 
intricate network of interactions with the LCR, globin gene promoters and other 
c/5-acting elements. The transcription factors can be broadly divided into three main 
families: the GATA family, the Kriippel family and nuclear factor erythroid family 
(Perry and Sereq, 2002). 
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1.2.2.3.1 GATA Family 
This group of transcription factors is characterized by the target sequence they 
bind - (T/A)GATA(A/G). They belong to the zinc finger family. GATA-1 is required 
for erythrocyte, megakaryocyte, mast cell and eosinophile differentiation (Perry and 
Sereq，2002; Welch et al., 2004). GATA-1 binding sites are found in all globin gene 
promoters and in HSl to HS5. Depending the transcriptional environment, GATA-1 
can function as both an activator and a repressor. For example, GATA-1 activates e 
-globin gene expression, but in the presence of transcription factor YYl, they interact 
to silence the e -globin gene (Gong et al., 1991; Raich et al, 1995). GATA-1 also 
interacts with SP-1 (Fischer et al, 1993; Merika and Orkin, 1995), EKLF (Crossley et 
al.’ 1994; Merika and Orkin, 1995) and Friend of GATA-1 (FOG) (Letting et al., 2004; 
Vakoc et al, 2005) in regulating the activity of globin gene promoters. 
GATA-2 follows the expression pattern of GATA-1 from the very onset of 
hematopoiesis and its level diminishes when the erythrocytes approach maturation 
(Leonard et al, 1993). 
1.2.2.3.2 Kriippel-like Factors 
The Kriippel family consists of zinc finger motif and binds a CACC box or 
GC-rich sequences. Members that regulate erythroid cell development are fetal 
Kriippel-like factor (FKLF) and erythroid Kriippel-like factor (EKLF). FKLF 
activates embryonic globin gene expression and to a lesser extent the fetal globin gene 
(Asano et al, 1999; Asano et al., 2000; Harju et al., 2002; Mitsuma et al., 2005). 
EKLF, on the other hand, favors the binding to the CACC-boxes on the jS -globin 
gene rather than the 7 -globin gene (Harju et al., 2002; Perry and Sereq，2002; Chen 
and Bieker, 2004; Hodge et al., 2006). 
1.2.2.3.3 Nuclear Factor-Erythroid (NF-E) 
Nuclear factor-erythroid 2 (NF-E2) belongs to the basic-leucine zipper 
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heterodimer. It recognizes motif highly homologous to the AP-1 binding site -
(T/C)GCTGA(G/C)TCA(T/C), with conserved sequence upstream this sequence to let 
it be distinguished from the AP-1 binding site. NF-E2 is the heterodimer of p45NF-E2 
and pl8NF-E2. pl8NF-E2 belongs to the small Maf family and p45NF-E2 belongs to 
the cap'n'collar (CNC) of the basic-leucine zipper proteins (Andrews, 1998). NF-E2 
is reported to play a role in erythroid cell differentiation in mice (Nagai et al., 1998) 
and the p45NF-E2 domain is critical for activating /3 -globin gene expression (Bean 
and Ley, 1997; Blank et al., 1997) by recruiting RNA polymerase II to the jS -globin 
gene (Vieira et al, 2004). 
NF-E4 was first characterized in chicken erythroid cells as a stage-specific 
element in regulating /3-globin gene expression (Gallarda et al., 1989; Yang and 
Engel, 1994). Later, using K562 cells, enforced expression of NF-E4 was found to 
induce 了 -globin gene expression by interacting with ubiquitous transcription factor 
CP2 which then bound to the stage-selector element (SSE) in the y -globin gene 
promoter (Jane et al, 1995; Zhou et al, 2000; Zhou et al, 2004). 
NF-El is another erythroid-specific transcription factor that recognizes the 
sequence GGGATAGAG containing the GATA consensus motif. NF-El alone is 
insufficient to activate the globin gene promoter and requires the cooperativity of 
other transcription factors such as CP2 and displacement of Spl (Martin and Orkin, 
1990; Yu et al, 1990; McDonagh et al, 1991). 
1.2.2.4 Chromatin Remodelling 
The regulation of globin gene expression is a complex event. The interaction of 
the c/5-acting elements and trans-Mmg factors determines the activation or 
repression of the globin gene; and this stage, if gene transcription is to proceed, 
opening of the chromatin is the prerequisite so that transcription factors can assess 
their DNA-binding site. 
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Histories assemble with DNA to form nucleosomes which are the chief building 
blocks of chromatin. Four evolutionary conserved histone molecules are H2A, H2B, 
H3 and H4. The C-terminal of the histone molecule is critical for histone-histone and 
histone-DNA interactions. On the other hand, the N-terminal tail of the histone is 
believed to make secondary structures with DNA and adjacent nucleosomes that allow 
dynamic changes in the chromatin and alter the accessibility of the genome to other 
protein factors (Cheung et al., 2000). 
The modulation of chromatin structure by the histone tail to initiate gene 
expression involves histone phosphorylation and acetylation. When exposed to 
growth factors, ERK pathway induced the phosphorylation of H3 and brought about 
transcriptional activation of immediate-early genes (Thomson et al., 1999). Earlier 
experiments on histone acetylation in lymphocytes demonstrated that transcriptional 
active genes were enriched in acetylated histone. Acetylation was brought by histone 
acetylase while histone deacetylase removed acetylation which repressed 
transcriptional activity (Turner, 1991). 
Active chromatin domain is achieved not only by histone acetylation but also 
DNA hypomethylation. DNA methylation is catalyzed by DNA methyltransferase 
(DNMT). Methylated DNA and histone hypoacetylation together will make the 
chromatin inaccessible for transcription (Fathallah and Atweh, 2006). Phosphorylation, 
acetylation and methylation are three inter-dependent events which tightly control the 
genome activity. 
1.2.2.5 Intergenic Sequences 
Apart from the transcription of the five genie regions, non-coding transcripts 
over the LCR and in between the globin gene coding regions had been identified. 
Such transcription of the intergenic regions in the jS -globin cluster occurred on the 
same strand as that of the globin genes and was erythroid-specific. The level of 
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intergenic transcription was correlated with the DNase I sensitivity in the /B -globin 
cluster. Mutation in the intergenic transcripts of the /3 -globin reduces DNase I 
sensitivity and /3 -globin transcription (Gribnau et al., 2000). 
The loss of 7.2kb of the intergenic 7 - 6 region upstream of the 6 -gene resulted 
in high level of fetal hemoglobin and interrupted the normal gamma-to-beta globin 
switching event (Bank et al, 2005). 
1.3 Mechanisms of Hemoglobin Switching 
Two mechanisms have been used to describe the control of globin gene 
switching: autonomous silencing and competition among the globin genes for 
interaction with LCR. 
1.3.1 Autonomous Silencing 
Autonomous silencing is observed in switches from £ to 7 during primitive 
erythropoiesis and from 7 to during definitive erythropoiesis (Li et al., 1998). 
Early studies on the e promoter deletion analysis showed that mutation of GATA-1, 
YYl or SPl sites upstream the e promoter abolished e globin gene silencing 
(Raich et al., 1995). As discussed in section 1.2.2.2.3, a silencer element was located 
in the proximal a promoter containing two DR sequences which could bind an 
orphan nuclear receptor called chicken ovalbumin upstream promoter-transcription 
factor (COUP-TF) and DRED (Filipe et al, 1999). 
Mutations in GATA-1 and Octl binding sites on the 7 -globin gene promoter 
resulted in the persistent increased in the fetal hemoglobin level and thus explained 
the roles of GATA-1 and Octl in 7 -globin silencing (Liu et aL, 2005). In addition, a 
DR element was also located in the 7 -globin gene promoter and mutation in this DR 
element increased the expression of ^ 7 expression (Omori et al., 2005). 
1.3.2 LCR and Globin Gene Interaction 
Gene competition was initially proposed to explain the hemoglobin switching 
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event in transgenic mice. When the LCR was either linked to the 7 -and jS -globin 
genes alone, there was no proper developmental regulation. Only when the 7 and J3 
genes were linked in correct order with the LCR, the developmental control was 
restored (Peterson and Stamatoyannopoulos, 1993; Harju et al., 2005). Proximity to 
the LCR offered an advantage for transcription as evidenced by gene placed in close 
proximity to the LCR was detected first (Harju et ai, 2005). 
The LCR is distant from the globin gene promoters. How does the LCR 
accomplish transcriptional activation? This is still a question to the scientists and there 
are four models proposed to explain the phenomena: looping, tracking, facilitated 
tracking and linking, but not a single model can fully resolve the mystery. 
The looping model suggests that the LCR functions as a holocomplex in which 
transcription factors are bound to the hypersensitive sites and this complex will loop 
out intervening DNA sequence and then form an active transcription complex at the 
globin gene promoter (Tang et al., 2002; Tolhuis et al., 2002). In the tracking model, 
transcription factors bind to specific sequence in the LCR and the complex will track 
linearly along the yS -globin locus until it reaches a right promoter to initiate a 
complete transcription process (Tuan et al, 1992; Kim and Dean, 2004). The 
facilitated tracking model combines both aspects of the looping and tracking model. 
Transcription factors and other coactivators first bind to the LCR and intervening 
DNA is looped out. Transcription factors are then released from the LCR and 
delivered to the proximal promoter region. The LCR will move along the DNA until it 
encounters an appropriate globin gene promoter bound with transcription factors 
(Blackwood and Kadonaga, 1998; Petrascheck et al, 2005). Finally，the linking model 
proposes that chromatin facilitator proteins first define the chromatin domain to be 
transcribed and mediate sequential binding of transcription factors. The transcription 
factors are linked to other by linking proteins and the LCR are linked to the globin 
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gene by non-DNA-binding facilitator proteins (Engel and Tanimoto, 2000). 
1.4 Hemoglobinopathies 
Hemoglobinopathy is a kind a genetic defect in the hemoglobin gene clusters 
resulting in the reduced synthesis of hemoglobin or the production of abnormal 
hemoglobin. It embraces a large number of hemoglobin variants and three common 
hemoglobinopathies include a -thalassemia, /5 -thalassemia and sickle cell anemia. 
1.4.1 a -thalassemia 
a -thalassemia is characterized by the inadequate synthesis of a -globin, usually 
due to deletions in the a -globin gene. Mutations in the a -globin gene promoter or 
the coding sequence is rarely observed. (Hoffbrand et aL, 2001). In normal individual, 
there are four copies of a -globin gene and severity of the disease depends on the 
number of copies of a -globin gene being deleted. A fetus cannot survive which 
results in a clinical condition called hydrops fetalis or intra uterine death if he/ she 
loses all four copies of a -globin gene. The loss of three copies of a -globin gene 
results in Hemoglobin H ( 4 ) Disease with a moderate to severe anemia and 
splenomegaly. If this happens in fetal stage, Hb Baits ( 7 4) occurs (Sarnaik, 2005). 
Although uncommon, there are structural variants of a -globin - Constant Spring 
(HbCS) which is prevalent in Asian population (Tangvarasittichai et al, 2005) and 
hemoglobin Woodville which is caused by an amino acid change from aspartic acid to 
tyrosine at position 6 of the a 1-globin gene (Viprakasit et al., 2006). 
1.4.2 fi -thalassemia 
Unlike a -thalassemia, yS -thalassemia is caused by point mutations in the 
promoter region or the globin gene coding sequence itself. Up till now, there have 
been more than two hundred point mutations reported in /9 -thalassemia patients. The 
reduced level of normal ^ -globin disrupt the normal ratio of a - t o yS -globin leaving 
an excess a -globin chains. The excess a -globin chains will precipitate in red blood 
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cell and lead to hemolytic anemia (Olivieri, 1999; Rund and Rachmilewitz, 2005). 
The amount of normal /3 -globin grades the severity of 冷 - t h a l a s s e m i a to three 
classes. Since there are many mutations leading to j3 -thalassemia, these mutations in 
general designated as either or /S + mutations. No 冷 globin is produced with a 
mutation, and only a small fraction of the normal amount of beta globin is produced 
with a + mutation. People with homozygous ^ mutation are said to be thalassemia 
major, with homozygous mutation are thalassemia intermedia and with a single 
copy of + mutation are thalassemia minor (Weatherall, 2000; Samaik, 2005). 
Mutations leading to ^ -thalassemia can be divided into four main categories: 
mutations that cause defective /S -globin gene transcription (for examples, mutations 
in promoter or enhancer), mutations in the jS -globin gene coding sequence that give 
unstable hemoglobin, mutations that cause abnormal processing of /3 -globin mRNA 
and mutations that result in abnormal translation of fi -globin mRNA. 
A number of mutations have been reported in the -globin gene promoter or 
enhancer which reduces the synthesis of -globin (Bianco et al., 1997). The 
exhibition of certain -thalassemia genotype is dependent on the ethnic group. 
Unstable hemoglobin production was reported as a result of mutation in exon 3 of the 
/5 -globin gene (Kazazian et al., 1992). RNA splicing problems can be detrimental in 
thalassemia patients (Ley et al, 1982). In southern China, a C to T mutation in the 
second intervening sequence of the /3 -globin gene accounts for 20% of the 
-thalassemia cases. Such mutations causes aberrant RNA splicing and (3 ® 
thalassemia (Lewis et al., 1998). Mutation in the splice site of exon 1 inhibits the 
pre-mRNA splicing event which gives phenotype (Vidaud et al., 1989). There are 
also reports on mutations in the 0 -globin gene CAP site and polyadenylation signal 
which result in the synthesis of premature and unstable 0 -globin mRNA (Cai et al., 
1992). Inhibition of the translational machinery can be observed in patients carrying 
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amber nonsense mutation at amino acid 17 in Chinese (Chang et al., 1979) and at 
amino acid 39 in Sardinia (Trecartin et aL, 1981). 
Different thalassemia patients suffer from various problems, depending on the 
severity of the disease. But most of the problems arise from the ineffective 
erythropoiesis which lowers the oxygen carrying capacity of blood and hypersplenism 
due to extramedullary erythropoiesis (Modell, 1974). Anemia, fatigue and growth 
retardation will be resulted. Bone deformities are brought by the increased blood 
production in bone marrow which cause bone expansion in patients' body (Modell, 
1974). Severe anemia taxes other organs to work harder than usual that lead to organ 
failure (Weatherall, 2001; Rund and Rachmilewitz, 2005). 
1.4.3 Sickle Cell Anemia 
Sickle cell anemia is the most common inherited blood disorder in the United 
States and it is named because of the occurrence of red blood cells of a sickle shape. 
The sickle cells arise from a point mutation in the /3 -globin gene where there is a 
base substitution of A to T resulting in an amino acid change from glutamic acid to 
valine at position 6. This substitution produces insoluble hemoglobin crystals (termed 
HbS, a 2 ^  2 ) under low oxygen tension. The deoxygenated form of HbS 
polymerizes into long fibrils which block different areas of vascular system causing 
vaso-occlusion and organ infarction (Claster and Vichinsky, 2003). 
1.5 Therapies for ^ -thalassemia 
1.5.1 Blood Transfusion 
Traditional therapy of thalassemia major is blood transfusion to help prevent 
severe anemia and allow for more normal growth and development. But blood 
transfusion may cause excessive iron deposition in heart, liver and kidney so patients 
have to inject iron-chelating agents frequently (Schrier and Angelucci, 2005). 
The first iron-chelating agent used in combination with blood transfusion is 
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deferoxamine (DFO). However, DFO is not absorbed in the gastrointestinal tract and 
has to be injected sub-cutaneously which brings a lot of troubles to patients. Though 
DFO reduces hepatic iron content, patients still die of iron overload as DFO imposes 
an adverse effect on cardiac contractility and rhythmicity (Borgna-Pignatti et al., 
2005). Because of these constraints, another oral iron-chelator deferiprone is used 
instead. In 2005, a novel oral iron chelator approved by FDA - deferasirox (Exjade by 
Novartis) appears on the market (Neufeld, 2006). 
1.5.2 Bone Marrow Transplantation 
Bone marrow transplantation is given as a treatment alternative for thalassemia 
major patients in the hope that the hematopoietic stem cells from healthy bone 
marrow will differentiate into normal erythrocyte and restore the normal hemoglobin 
synthesis machinery. However, a successful transplantation to bring the patients to 
disease-free can only be achieved when the donor's bone marrow is fully matched 
with the patients. Otherwise, the patients receiving transplantation will risk having 
transplant complications, chronic graft-versus-host disease or reoccurrence of 
thalassemia symptoms (Evans, 1992). 
1.5.3. Gene Therapy 
Correction of the defective genotype of the hematopoietic stem cell provides a 
promising approach to treat /S -thalassemia if potential problems like low-level of 
expression and transient effect can be overcome. The first application of gene therapy 
in /3 -thalassemia mouse model was the delivery of a normal 曰-globin gene 
constructs to the hematopoietic stem cells using retroviral vectors. The drawbacks of 
using retrovirus were the low efficiency of gene transfer and the low level of 
expression of the exogenous DNA (Stamatoyannopoulos, 1992; Pawliuk et al., 1998). 
Later, lentiviral vectors are used for stable and long term expression of the globin 
gene. Promising results were obtained in mice with beta-thalassemia intermedia 
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following engraftment with bone marrow cells transduced with a lentiviral vector 
carrying the human -globin gene. Thalassemic symptoms such as ineffective 
erythropoiesis and extramedullary hematopoiesis were improved (May et al, 2002; 
Rivella et «/.,2003). 
1.6 Gene Switch Therapy 
In some jS -thalassemia patients, they suffer not only mutations in the /3 -globin 
gene but also the 7 -globin gene and result in a clinical condition called hereditary 
persistent of fetal hemoglobin (HPFH). Patients with co-occurrence of jB 
-thalassemia traits and HPFH had a milder thalassemia symptoms than those with jS 
-thalassemia alone; thus it was speculated that the high level of fetal hemoglobin in 
HPFH patients ameliorates the symptoms by replacing the defective adult hemoglobin 
(Natta et aL, 1974). 
It would be an alternative to treat /5 -thalassemia or sickle cell disease if the 
patients' 7 -globin gene could be reactivated. At 1980s, patients administered with 
the anticancer drug, 5-azacytidine, were found to have a higher level of HbF. This 
drew attention of scientists to find out more the "gene switch" therapy. The drug was 
then tested in baboons (DeSimone et al, 1982) and patients with sickle cell anemia 
and severe thalassemia and an increase in HbF production was detected (Ley et al, 
1982; Humphries et aL, 1985). 5-azacytidine is an inhibitor of DNA 
methyltransferease (DNMT) which induces hypomethylation of the transcriptionally 
silent 7 -globin gene. This drug is not in use for treating thalassemia because as it is 
highly cytotoxic to bone marrow and very likely to cause cancer in patients though no 
direct evidence could be found (Ley and Nienhuis, 1985). 
1.6.1 Pharmacological Induction of HbF 
Discovery of pharmacological agent, 5-azacytidine, in reactivating 7 -globin 
gene sheds light on finding safer substitute for clinical use. There are now a number 
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of compounds reported to be able to induce fetal hemoglobin production, however, 
only hydroxyurea is approved by FDA to treat sickle cell disease and in clinical use. 
1.6.1.1 Hydroxyurea 
Hydroxyurea (HU) is a relatively weak inhibitor of ribonucleotide reductase 
which inhibits DNA synthesis and is originally used in treatment of chronic 
myelogenous leukemia and other cancers (Elford, 1968). In the 90s, FDA approved 
the use of HU in treating sickle cell anemia after pilot study of the ability of HU in 
inducing HbF in anemic patients. Administration of HU to these patients reduced the 
frequency and episode of pain (Piatt et al., 1984). HU is a non-DNA-methylating 
agent and a S-stage specific compound which accelerates the erythroid regeneration 
owing to the decrease in the absolute reticulocytes after HU treatment. The rapid 
erythroid regeneration increases the chance of F cell formation by premature 
commitment of earlier progenitor cells and hence y -globin gene reactivation 
(Galanello et al.’ 1988). The number of erythroid burst-forming unit (BFU-E) 
colonies decreases with an increasing dose of HU. Such suppression accelerates 
erythroid regeneration and hence the HbF level (Yang et al., 1997; Baliga et al., 2000). 
HU is also tested in patients with -thalassemia (Loukopoulos et al, 1998; de Paula 
et al” 2003) and the drug reduces the blood transfusion requirement of young patients 
(Bradai et al., 2003), reduces extramedullary hematopoiesis and augments HbF 
concentration (Saxon et al., 1998). 
The drawbacks of long-term usage of HU are its myelotoxicity, carcinogenicity 
and limited efficacy. Some patients simply do not respond towards HU therapy 
(Halsey and Roberts, 2003; Zimmerman et al, 2004). Due to these shortcomings, HU 
has been used in combination with other drugs like phenylbutyrate (Olivieri et al., 
1997; Hoppe et al.’ 1999) and to enhance the HbF inducing ability. 
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1.6.1.2 Butyrate 
Butyrates, including butyric acid, sodium butyrate, arginine butyrate and sodium 
phenylbutyrate), are short chain fatty acids that are under clinical trials on the road to 
become another drug that can be approved to be used to treat sickle cell anemia and 
13 -thalassemia. Butyrates were given to murine erythroleukemia cell line (Kameji et 
al.’ 1977), chicken (Ginder et al, 1984) and sheep (Perrine et al, 1988) and it was 
discovered that the fetal to adult globin gene switch was suspended and there was an 
accumulation of fetal hemoglobin. Butyrate was later tested on sickle cell anemia and 
-thalassemia patients and encouraging results were obtained. The drug was able to 
stimulate HbF production in BFU-E and recruit more erythroblasts to produce HbF 
(Perrine et al., 1989). 
The mechanism of HbF induction by butyrate, or the short chain fatty acid 
(SCFA), is partly mediated by inhibition of histone deacetylase. Inhibition of histone 
deacetylase increases acetylation of histone which opens the chromatin structure and 
makes DNA more accessible to transcription factors (Turner, 1991). Transient 
transfection assay revealed that butyrate increased y -promoter activity (Safaya et al, 
1994) and mutational analysis showed that the duplicated CCAAT-boxes and the 
CACCC-box were necessary for transcriptional activation of the y -globin gene 
(McCaffrey et al., 1997). More detailed studies on the CCAAT-boxes identified a 
butyrate response elements (BRE) on the -822 to -893 region of the 八 y -promoter and 
upon butyrate induction, the protein-DNA interactions in the BRE were altered 
suggesting that butyrate modified the transcription factor binding at BRE so as to 
activate the ^ y -promoter (Pace et al.’ 2000). 
Although it is widely accepted that butyrate acts at transcriptional level, there is 
new insights proposing the role of butyrate on increasing translation efficiency of y 
-globin mRNA (Weinberg et al, 2005). Though studies on butyrate action are intense, 
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some unwanted side-effects from butyrate therapy are unavoidable. For instances, the 
offensive odor from the oxidation of butyrate to acetate, endema and epigastric 
discomfort severely affect the patients' daily life (Dover, 1997). 
1.6.1.3 Summary 
The drawbacks of HU and butyrate in treatment stimulate the exploration of 
other potential HbF-inducing drugs. These drugs are tested in mice and human 
erythroleukemia cell line K562. They can be classified as four major groups: 
ribonucleotide reductase inhibitors, histone deacetylase inhibitor, DNA 
methyltransferase inhibitor and DNA-binding drugs. Table 1-1 summarizes their mode 
of action. 
Table 1-1. Fetal hemoglobin inducing drugs classified by their mode of actions. 
Mode of Action Examples 
Ribonucleotide Inhibit DNA synthesis Didox (lyamu et al., 
reductase inhibitors (Elford, 1968) 2000), Trimidox (lyamu et 
al, 1998) 
Histone deacetylase Cause hyperacetylation of Short chain fatty acids 
inhibitor histories and open up (Liakopoulou et al., 
chromatin (Turner, 1991; 1995), Apicidin (Witt et 
McCaffrey et al, 1997) al, 2003), Trichostatin A 
(Swank et a/., 2003) 
DNA methyltransferase Cause hypomethylation and 5-aza-2‘ -deoxycytidine 
inhibitor open up chromatin (Koshy et al, 2000; 
(Fathallah and Atweh, 2006) Saunthararajah et al., 
2003) 
DNA-binding drugs Form covalent DNAadducts, Cisplatin (Bianchi et al, 
distort chromatin structure 2000), Mithramycin 
and protein binding, (Fibach et al., 2003), 
selectively binds at GC-rich Chromomycin (Bianchi et 
(Davies et al，2000) al., 1999)，Tallimustine 
(Bianchi et al” 2001), 




As our laboratory discovered and isolated a compound from Chinese Medicine 
. which was able to induce fetal hemoglobin production more potent than that by 
hydroxyurea, in this project, I would: 
a. determine the dose of LC978 for maximal fetal hemoglobin production by 
human HbF ELISA; 
b. identify the possible signal transduction pathways mediated by LC978 by 
microarray; 
c. evaluate the roles of the pathways identified in (b) by cell-based 
phosphorylation ELISA; 
d. confirm the roles of the pathways in regulating 7 -globin gene expression using 
specific inhibitors. 
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Chapter 2 Induction of HbF by LC978 in K562 
2.1 Introduction 
A random screening for Traditional Chinese Medicine (TCM) which possessed 
the ability to induce hemoglobin in K562 was carried out in our laboratory. Different 
species of TCM were extracted in ethanol and the extracts were used to treat K562. 
The total hemoglobin content of K562 was measured by 3， 3 丨，5, 
5'-TetramethyIbenzidine (TMB) staining assay. Among the 66 species of TCM tested, 
one species first designated as T961 had a significant effect on inducing hemoglobin. 
T961 came from Trichosanthes kirilowii Maxim. The percentage of hemoglobin 
positive cells was as high as 55%, compared to only 19% in erythropoietin-treated 
positive control. The extract from T961 was further purified and different fractions 
were analyzed. The fraction with hemoglobin inducing activity was further separated 
and analyzed by high performance liquid chromatography (HPLC). A pure lead 
compound designated as LC978 was purified by HPLC and was the key factor in 
inducing hemoglobin production in K562. 
A dose-response assay of LC978 was then carried out in K562. The effective 
dose causing 50% of the maximal hemoglobin production (ED50) was 2.38ng/ml with 
LC978 while the ED50 for hydroxyurea was 7.22|xg/ml indicating the higher efficacy 
of LC978 in inducing hemoglobin. The cytotoxicity of LC978 was also evaluated 
using MTT assay. The inhibitory concentration causing 50% growth inhibition (IC50) 
of LC978 was far much lower than that of hydroxyurea: 841.9ng/ml for LC978 and 
63.1 lug/ml for hydroxyurea (Xing, 2003). The IC50 of LC978 was about 400-fold 
lower than its ED50 which implied that the drug did not impose any inhibitory or 
toxic effect on the cells when treated at its ED50. In short, LC978 showed a higher 
efficacy and lower toxicity when compared to the currently used drug hydroxyurea. 
In order to study the mechanism of HbF induction by LC978, a suitable cell 
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model should possess the following criteria: 1) comes from Homo sapiens; 2) belongs 
to the erythriod lineage which is able to produce hemoglobin; 3) able to induce 
hemoglobin production upon treatment with agents like 5'-azacytidine and 
hydroxyurea; and 4) has a low level of endogenous hemoglobin such that "induced" 
hemoglobin can easily be measured. K562 is the cell system which satisfies all the 
above criteria and is employed throughout the project. 
K562 is the hematopoietic malignant cells isolated from the bone marrow of the 
patients with chronic myelogenous leukemia (CML) (Lozzio and Lozzio, 1975). This 
cell line spontaneously differentiates into progenitors of the erythrocytic, granulocytic 
and monocytic series (Lozzio et al, 1981). It exhibits an embryonic/ fetal phenotype 
which expresses both £ - and y -globin; and upon induction with hemin, the cells 
are able to synthesize more embryonic and fetal hemoglobin but not the adult 
hemoglobin (Rutherford et al., 1981). The lack of expression of the adult hemoglobin 
in this cell system drives researchers to investigate whether the cw-regulatory 
elements or the trans-acting factors were involved. The /3 -globin gene was cloned 
from K562, transfected to non-erythroid cell line and RNA transcripts produced were 
analyzed by Northern blot and S1 nuclease protection. It was found that the amount 
and size of RNA produced was comparable to those obtained with a normal /3 -globin 
gene (Donovan-Peluso et al, 1984). Another experiment on the restriction 
endonuclease analysis of genomic K562 revealed the integrity of /3 -globin gene in 
the cell (Fordis et aL, 1984). These results suggested the cellular environment in K562 
was altered in a way that is unfavorable for /3 -globin gene expression. This was 
evidenced when sickle globin {/S ) gene was transfected to K562 there was no 
detectable j3 mRNA expression (Young et al•’ 1985). Though there are a number of 
studies reporting that the /3 -globin gene expression is barely detectable, Mookerjee 
et al reported that isolation of a variant clone of K562 which was able to produce 
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significant amount of yS-globin mRNA (Mookerjee et al., 1992). The availability of 
K562 clones that express /5 -globin and clones that do not express /3 -globin provide a 
good model to study the difference in the trans-acting factors involved in regulating 
the phenotypes of these two cell clones. Later, a repressor protein termed Beta Protein 
1 (BPl) was identified to be involved in the negative regulation of human -globin 
gene (Chase et al., 2002). Inhibition of BPl expression by RNA interference causes a 
drastic elevation of /3 -globin promoter activity and hence the /3 -globin mRNA 
without affecting the level of other transcription factors like EKLF and GATA-1 
(Zoueva and Rodgers, 2004). 
The objectives of this part of the project were to determine the dose of LC978 
and hydroxyurea for maximum induction of hemoglobin in K562 and to verify the 
fetal hemoglobin inducing ability of LC978 at transcriptional and translation levels. 
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2.2 Materials 
2.2.1 Chemicals and Reagents 
Chemical/ Reagent Source, Catalog Number 
RPMI Medium 1640, powder Gibco 23400-021 
Dulbecco's Phosphate-Buffered Saline ( D - P B S ) , . 
Gibco 21600-010 
powder 
Sodium Bicarbonate (NaHCOs), Cell Culture Tested Sigma S5761 
Fetal Bovine Serum, Qualified Gibco 10270-106 
Antibiotic-Antimycotic (1OOX)，liquid Gibco 15240-062 
Citric Acid Monohydrate Merck A336848 
Sodium Dihydrogen Phosphate (NaHbPOd), anhydrous Sigma S0751 
Sodium Hydroxide (NaOH), pellets Sigma S8045 
Hydrogen Peroxide (H2O2, 30% w/w) BDH 101284N 
Human Hemoglobin A2, Ferrous, Img/ ml Sigma H0266 
LC978, 10|ag/ml 
Hydroxyurea (HU) Sigma H8627 
Diethyl pyrocarbonate (DEPC) Sigma D5758 
Trizma® Hydrochloride Sigma T5941 
Guanidinium Thiocyanate Sigma G9277 
Cesium Chloride Sigma C4036 
RNaseOUT Recombinant Ribonuclease Inhibitor Invitrogen 10777-019 
Agarose, Seakem LE FMC 50004 
1 Kb Plus DNA Ladder Invitrogen 10787-018 
Sodium Carbonate (Na2C03) Sigma S7795 
Sodium Bicarbonate (NaHCOs) Sigma S6297 
Trizma® Base, NH2C(CH20H)3 Sigma T6066 
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Sodium Chloride (NaCl) RDH 31434 
Tween 20 US 20605 
Bovine Albumin Fraction V Gibco 11018-017 
3, 3', 5, 5'-Tetramethylbenzidine (TMB) Sigma 527A-1KT 
Dimethyl sulfoxide (DMSO) Sigma D2650 
Sulphuric Acid (H2SO4), 98% Ajax Chemicals 
Triton X-100 Fluka 93426 
0.4% Trypan Blue Solution Sigma T8154 
2.2.2 Kits 
Kit Source, Catalog Number 
Hemoglobin, Plasma Kit Sigma 527A-1KT 
RQ1 RNase-free DNase Promega 9PIM610 
M-MLV Reverse Transcriptase, 200U/ul (with 5X 
^ Invitrogen 28025-013 
First Strand Buffer & O.IM DTT) 
Thermoprime Plus DNA Polymerase, 5U/li1 (with lOX 
P ABgeneAB-0301 
Reaction Buffer & 25mM MgCb) 
iQ™ SYBR Green Supermix BioRad 170-8880 
Human Fetal Hemoglobin (HbF) ELISA Quantitation Bethyl Laboratories 
Kit E80-136 
2.2.3 Buffers and Solutions 
Buffer/ Solution Preparation 
1 pack of RPMI Medium 1640 powder and 
2.0g sodium bicarbonate was added to 950ml 
Milli-Q H2O. The pH of the mixture was 
RPMI Medium 1640 
adjusted with IM NaOH to pH 7.2. Milli-Q 
(2.05mM L-glutamine, 25mM , ^ 
H2O was added to make up the medium to IL. 
HEPES Buffer and 0.02M _ … 
The medium was filtered through 0.22|j,m filter. 
Complete RPMI was prepared by adding FBS 
and PSF at final concentrations of 10% and 1% 
respectively. 
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IX PBS (2.67mM KCl, 1.47mM 1 pack of PBS powder was dissolved in IL 
KH2PO4, 137.93mM NaCl and Milli-Q H2O. The solution was autoclaved, 
8.1 OmM Na2HP04) cooled to room temperature and stored at 4°C. 
TMB stock solution (for TMB 1 bottle of TMB powder was dissolved in 45ml 
assay), 6mg/ml acetic acid. 
10.22g citric acid and 12.38g NaHaPOg were 
TMB working buffer dissolved in 850ml Milli-Q H2O. The pH of the 
(0.05M citric acid and O.IM solution was adjusted with NaOH to pH 5.0. 
NaH2P04), pH 5.0 Milli-Q H2O was added to make up the solution 
to IL. 
TMB working solution (0.05M This solution was freshly prepared. For 20.4ml 
citric acid, O.IM NaHzPO*，0.6% TMB working solution, 400^il 30% H2O2 and 
H2O2 and 60|ig/ml TMB) 200|il TMB stock solution were added. 
0.15g HU was dissolved in 3ml PBS and 
50mg/ml Hydroxyurea filtered through 0.22|im filter under sterile 
condition. 
Agarose powder was added to IX TAE Buffer 
1% Agarose solution to final concentration of 1% (w/v). The solution 
was autoclaved and kept in 65 °C. 
Coating Buffer, 50mM 0.0795g NazCOs and 0.357g NaHCCb were 
Carbonate-Bicarbonate, pH 9.6 dissolved in 100ml Milli-Q H2O. 
3.125g of Trizma hydrochloride was dissolved 
in 15ml DEPC-treated H2O. pH of the solution 
IM Tris-HCl, pH 7.5 was adjusted to pH 7.5 using HCl. 
DEPC-treated H2O was added to make up the 
solution to 20ml. 
50g of guanidium thiocyanate was dissolved in 
10ml of IM Tris-HCl (pH 7.5), DEPC-treated 
H2O was added to make up the solution to 
4.0M Guanidinium Thiocyanate 100ml. The solution was filtered through a 
Whatman No.l Filter and stored at room 
temperature. Just before use, p-mercaptoethanol 
was added to a final concentration of 1%. 
87.85g of CsCl was dissolved in 92ml of 
5.7M Cesium Chloride DEPC-treated H2O. The solution was 
autoclaved and stored at room temperature. 
Absolute ethanol was added to DEPC-treated 
RNase-free 70% Ethanol tt � ^ , … . ， / � 
H2O to a final concentration of 70% (v/v). 
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7.38g of sodium acetate was dissolved in 20ml 
DEPC-treated H2O. The pH of the solution was 
3M Sodium Acetate, pH 5.2 adjusted with acetic acid to pH 5.2. DEPC-H2O 
was added to make up the solution to 30ml. The 
solution was autoclaved. 
6.057g Tris base and 8.182g NaCl were added 
Tris-Buffered Saline (TBS) . . 
to 900ml Milh-Q H2O. The pH of the solution 
(50mM Tris and 0.14M NaCl), , ^ 
was adjusted with HCl to pH 8.0. Milli-Q H2O 
pH 8.0 
was added to make up the buffer to 1L. 
Wash Solution The Wash Buffer was freshly prepared. Tween 
(50mM Tris, 0.14M NaCl and 20 was added to IX TBS at final concentration 
0.05% Tween 20) of 0.05% (v/v). 
Blocking Solution (50mM Tris, BSA was added to IX TBS at final 
0.14M NaCl and 1%BSA) concentration of 1% (w/v). 
Sample/ Conjugate Diluent Tween 20 was added to Blocking Solution at 
(50mM Tris, 0.14M NaCl, 1% final concentration of 0.05% (v/v). 
BSA and 0.05% Tween 20) 
0.03g TMB powder (from the Hemoglobin, 
TMB Stock Solution (for Plasma Kit) was dissolved in 5ml DMSO. The 
ELISA), 6mg/ml solution was light-sensitive and had to be 
protected from light. 
2.555g Citric acid and 3.095g NaH2P04 were 
TMB Substrate Buffer added to 200ml Milli-Q H2O. The pH of the 
(0.05M citric acid and O.IM solution was adjusted with NaOH to pH 5.5. 
NaH2P04) Milli-Q H2O was added to make up the solution 
to 250ml. 
TMB Substrate Solution This solution was freshly prepared. For 12ml 
(0.05M citric acid, O.IM substrate solution, 200^1 of 6mg/ml TMB Stock 
NaH2P04, O.lmg/ml TMB and Solution and 4|il of 30% H2O2 were added to 
0.01% H2O2) 12ml pre-warm TMB Substrate Buffer. 
10.7ml H2SO4 was added slowly to 70ml 
2M Stop Solution Milli-Q H2O. Milli-Q H2O was added to make 
up the solution to 100ml. 
Triton X-100 was added to Milli-Q H2O at a 
20% Triton X-100 
final concentration of 20% (v/v). 
� „ T . ^ ^ 20% Triton X-100 was added to TBS at a final 
Cell Lysis Buffer 
concentration of 1% (v/v). 
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2.2.4 Primers 
Reference Description/ Tm 
Code Sequence (°C) 
size (bp) 
Human GAPDH, upper primer 
MF214 , 仲 p 62 
5'-ACC ACA GTC CAT GCC ATC AC-3' 452 
Human GAPDH, lower primer 
MF 215 62 
5'-TCC ACC ACC CTG TTG CTG TA-3' 
Human 八 7 , ° 7 -globin gene, upper primer 
MF 514 68 
5,-CAG ACG CCA TGG GTC ATT TCA C-3' 
T ^ 380 
Human 7 , 7 -globin gene, lower primer 
MF 515 68 
5'-GGT GAA TTC TTT GCC GAA ATG GAT-3' 
2.2.5 Equipment and Other Consumables 
Equipment/ Consumables Source, Catalog Number 
Bench-top centrifuge Eppendorf 5415D 
Bench-top centrifuge (refrigerated) Eppendorf 5804R 
Bench-top centrifuge (for microplates) Beckman 
Ultra-Centrifuge Beckman XL80 
Swing buckets Beckman SW55Ti 
Ultracentrifuge tubes Beckman 326819 
Thermal Cycler MJ Research PTC-200 
iQ5 Real-Time PCR Detection System BioRad 
200)11 Thin Wall Tube Strips BioRad 223-9469 
0.2ml Thin Wall 8-Cap Strips BioRad 223-9472 
Hemacytometer Bright-Line 
96 M i c r o W e l l ™ Plates Nunclon™A, round bottom Nunc 163320 
96 Well Clear Flat Bottom Polystyrene High Bind 
Coming 9018 
Microplate 
Microplate Reader System, SpectraMax 250 Molecular Devices 
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RNaseZAP Sigma R2020 
ART® Aerosol Resistant Tips Molecular BioProducts 
2.2.6 Maintenance of K562 
The cultures were grown in Complete RPMI and maintained by sub-cultured in fresh 
medium when the cell density reached 2 x 10^  cells/ml. The cultures were incubated 
in 37°C humidified CO2 incubator with 95% air and 5% CO2. 
2.2.7 Handling and Treatment of utilities for RNA isolation 
All glassware and forceps were baked in 220°C oven overnight before use. The 
microcentrifuge tubes were autoclaved. RNase-free H2O was prepared by treating 
Milli-Q H2O with 0.1% DEPC (v/v) for overnight. The bottle was inverted overnight 
and after that, the DEPC-H2O was autoclaved at 121°0 for 20 minutes to remove 
DEPC. To avoid RNase contamination, the working area was cleaned by RNaseZAP 




2.3.1 Dose-response and time-response study of LC978 in K562 by TMB assay 
10昭/ml of LC978 and 50mg/ml HU were diluted in complete RPMI to final 
concentrations of 200ng/ml and 200|Lig/ml respectively. 200|il of the diluted drugs 
were added to the first well of each row of a 96-well round-bottom microplate 
(triplicates for each drug) and 200|il of complete RPMI was added to the wells 
designated as negative control. A series of two-fold dilution, from 200ng/ml for 
LC978 and 200^g/ml for HU to 0.0977ng/ml for LC978 and 0.0977|Lig/ml for HU, 
was performed. K562 was diluted to 2 x lO* cells/ml with complete RPMI and lOOpl 
of the diluted culture (i.e. 2000 cells) was added to each well. Total eight identical 
setups were prepared and incubated in 37°C CO2 incubator. A plate was taken for 
TMB assay each day to determine the hemoglobin content of different treatments. 
The TMB assay was performed as described below: 
1. The plate was centrifuged at 300 x g for 10 minutes (25°C). 
2. The culture medium was removed by low vacuum suction to avoid disturbing the 
cell pellet. 
3. 100|il of TMB working buffer was added to each well to lyse the cells and the 
lysis took place at room temperature for 10 minutes. 
4. Hemoglobin A2 was used as standard in the assay. 20|xl of Img/ml Hemoglobin 
A2 was added to 180p.l of TMB working buffer and was serially diluted by two 
folds for eleven times. 
5. 200|a.l of TMB working solution was added to each well and the reaction was 
incubated in 37°C for 10 minutes. 
6. The absorbance was measured by microplate reader at OD600nm. 
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2.3.2 Detection of 7 -Globin Gene Expression in LC978-induced K562 by 
RT-PCR 
2.3.2.1 Induction of K562 with LC978 
Before induction, 5 x 10^  K562 cells were collected at 300 x g for 10 minutes and the 
cells were washed three times with cold IX PBS. The cell pellet was then lysed with 
3ml guanidine thiocyanate and the lysate was kept at -70°C for later use. 
Three flasks of 80ml K562 culture of initial cell density of 2000 cells/ml were 
prepared. 25|a.g/ml hydroxyurea was added to one flask of cells and 3.125ng/ml 
LC978 was added to another flask of cells. The remaining one was used as negative 
control. The cells were incubated in 37°C CO2 incubator for 4 days. All cells were 
collected at 300 x g for 10 minutes and the cells were washed three times with cold 
IX PBS. The cell pellet was then lysed with 3ml Guanidine thiocyanate and the lysate 
was kept at -70°C for later use. 
2.3.2.2 Semi-quantitative RT-PCR 
I. Extraction of total RNA by CsCI method (Chirgwin et al” 1979) 
The lysates were thawed at 65 °C. After thawing, the lysates were incubated at 65 °C 
for 5 minutes and chilled on ice immediately. The lysates were homogenized with 
sterile hypodermic syringe through a 21-gauge needle. 2.6ml of 5.7M CsCl solution 
was added to the ultra-centrifuge tubes and the level of CsCl was marked on the tube. 
The lysates were overlaid onto the CsCl cushion cautiously until the tubes were about 
to be filled up. The tubes were placed into the buckets and the buckets were balanced 
with a weight difference less than O.lg. The tubes were centrifuged at 33,700rpm at 
18°C for 18 hours using rotor SW55Ti. 
The supernatant was removed by aspiration using sterile glass pipette until the CsCl 
mark was reached. The remaining supernatant was removed by quickly inverting the 
tube. The pellet was air-dried completely. The bottom ring of the tube was cut off with 
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a sterile surgical blade. The pellet was resuspended in 400|a,l of DEPC-treated H2O 
and transferred to a 1.5ml microcentrifuge tube. 
40)il of 3M sodium acetate (pH5.2) and 1ml of absolute ethanol were added. The 
mixture was incubated at -20°C for 30 minutes and centrifuged at 14,000rpm at 4°C 
for 30 minutes in refrigerated centrifuge (Eppendorf 5804R). The supernatant was 
carefully removed. 1ml of 70% ethanol was layered to the RNA pellet and the tube 
was centrifuged at 13,200rpm for 5 minutes. The supernatant was carefully removed 
and the pellet was air-dried. The pellet was resuspended in 200|il of DEPC-treated 
H2O and the RNA was incubated in 65 °C for 10 minutes with intermittent vortexing 
to enhance dissolution. OD at 230, 260 and 280nm were taken to determine the 
concentration and purity of the RNA. 
II. RNase-free DNase Digestion 
To remove possible genomic DNA contamination in the purified RNA, all the RNA 
samples were subjected to DNase digestion. For each jig of RNA, Ijil of RQl 
RNase-free DNase lOX Reaction Buffer, l|il of RQl RNase-free DNase and 
appropriate amount of DEPC-treated H2O were added to a final volume of 10|il. The 
reaction was incubated at 37°C for 2 hours. l|il of RQl DNase Stop Solution was 
added to each tube to terminate the reaction. Inactivation of the DNase was done by 
incubating the reaction in 65°C for 10 minutes. 
III. Reverse Transcription 
For 20-|xl reaction volume, l|il of oligo (dT)i2-i8 and l|il of lOmM dNTP Mix 
were added to lOjil (i.e. Ijig) of DNase-treated RNA. The mixture was heated at 65°C 
for 5 minutes and chilled on ice immediately. 4|il of 5X First Strand Buffer, 2\i\ of 
O.IM DTT and l|il of 40units/|il RNaseOUT Recombinant Ribonuclease Inhibitor 
were added to the mixture which was then incubated in 37°C for 2 minutes. l|il (200 
units) of M-MLV RT were added to each tube and mixed by pipetting up and down. 
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The final mixture was incubated in 37°C for 60 minutes. The reaction was inactivated 
by heating at 70°C for 15 minutes. 
IV. PGR Reaction 
To each 20|il RT reaction, 80|il of Milli-Q H2O was added. The cDNA was boiled for 
15 minutes and chilled on ice immediately. For 25-\i\ PGR reaction, the followings 
were added to a microcentrifuge tube: 5|il of cDNA, 2.5|il of lOX PGR Reaction 
Buffer, 1.5…of 25mM magnesium chloride (MgCb), 0.5^1 of lOmM dNTP Mix, 
0.5(il of 25nM Forward Primer, O.S^ il of 25nM Reverse Primer, 0.1|j.l of Taq DNA 
polymerase (5U/|xl) and 14.4|al of autoclaved Milli-Q H2O. The reaction was 
performed in a Thermal Cycler with initial denaturation at 96。C for 4 minutes. 20 
cycles of denaturation at 96°C for 30 seconds, annealing at 60°C (for 7 -globin gene) 
or 56°C (for GAPDH normalization) for 30 seconds and extension at 72°C for 30 
seconds were performed. A final extension step at 72°C for 5 minutes was added and 
the reaction was cooled to 4�C. 
The PCR products were separated on 1% agarose gel at lOOV till the tracking dye 
reached 2/3 of the gel cast. 
2.3.2.3 Real-time PCR 
The PCR reaction was set by adding 25|il of 2X iQ SYBR Green Supermix, l|j.l of 
25pmole/|j.l Forward Primer, l|xl of 25pmole/jj-l Reverse Primer, 13|il of autoclaved 
Milli-Q H2O and \0\i\ of diluted cDNA. 
The PCR reaction was started with an initial activation step at 95°C for 3 minutes. 40 
cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds and 
extension at 72°C were performed. 
Data were analyzed by the iQ5 software according to manufacturer's instruction. The 
relative quantity of the 7 -globin gene was normalized to the relative quantity of the 
reference gene GAPDH. 
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2.3.3 Fetal Hemoglobin Analysis by Human Fetal Hemoglobin (HbF) ELISA 
Quantitation Kit 
2.3.3.1 Induction of K562 with LC978 
The induction was performed in round-bottom 96-well microplate as described in 
section 2.3.1 for 7 days. 
2.3.3.2 Quantitation of HbF induction 
I. Coating Capture Antibody onto Corning High Bind microplate 
On the sixth day after induction, l|il of Capture Antibody (A80-136A) was diluted in 
1 OOjjl of Coating Buffer for each well to be coated. The plate was sealed with a piece 
of parafilm to minimize evaporation. The plate was then incubated at 4°C overnight. 
After incubation, the Capture Antibody was removed by flipping the plate over the 
sink and tapping gently on paper towel to drain away excess liquid. The wells were 
washed with 200|j.l of Wash Solution for three times by flipping and tapping. 
II. Blocking 
200|j,l of Blocking Solution was added to each well and the plate was incubated at 37 
°C for one hour. After incubation, the Blocking Solution was removed and the wells 
were washed with 200|il of Wash Solution for three times. 
III. Sample Preparation 
The plate used for K562 induction as described in 2.3.3.1 was centrifuged at 300 x g 
for 10 minutes (25 °C) and the culture medium was removed by low vacuum suction. 
The cell pellets were lyzed in 20)il of Cell Lysis Buffer at 4�C for 30 minutes with 
intermittent rocking to ensure complete lysis. The lysates were centrifuge at 
13,200rpm for 10 minutes to pellet the debris. 2\i\ of the clear lysate was diluted with 
998|il of Sample/ Conjugate Diluent. 100|a.l of diluted lysate was added to each well. 
IV. Standard Preparation 
The Human Hemoglobin Calibrator (RC80-135-4) was serially diluted by 2 folds 
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according to the chart below: 
Standard Concentration Sample/ Conjugate 
Step Calibrator RC80-135-4 � ^ 
(ng/ml) Diluent 
1 500 2\i\ 2ml 
2 250 0.4ml from Step 1 0.4ml 
3 125 0.4ml from Step 2 0.4ml 
4 62.5 0.4ml from Step 3 0.4ml 
5 31.25 0.4ml from Step 4 0.4ml 
6 15.63 0.4ml from Step 5 0.4ml 
7 7.81 0.4ml from Step 6 0.4ml 
After dilution, 0.01% Triton X-100 was added to the diluted standard according to the 
following chart. 
Original Standard Total Volume Amount of 0.01% Final Standard 
Concentration (ng/ml) of Standard Triton X-100 added Concentration (ng/ml) 
500 1.6ml 0.4ml 400 
250 0.4ml 0.1ml 200 
125 0.4ml 0.1ml 100 
62.5 0.4ml 0.1ml 50 
31.25 0.4ml 0.1ml 25 
15.63 0.4ml 0.1ml 12.5 
7.81 0.4ml 0.1ml 6.25 
100|il of the above standards (w/ 0.002% Triton X-100) was transferred to assigned 
wells (duplicate for each dilution). The plate was incubated in 37°C for one hour. 
After incubation, samples and standards were removed and the wells were washed 
with 200|il of Wash Solution for five times. 
V. HRP Detection Antibody 
The Sheep anti-Human HbF-HRP conjugated antibody (A80-136P) was diluted at 
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1:5000 with Sample/ Conjugate Diluent. lOOjil of the diluted antibody was added to 
each well. The plate was incubated at 37°C for 90 minutes. After incubation, the 
unbound antibody was removed and the wells were washed with 200^1 of Wash 
Solution for five times. 
VI. Enzyme Substrate Reaction 
lOOjil of TMB Substrate Solution was added to each well. The plate was incubated at 
37°C for 5 to 30 minutes until a medium dark blue color was observed. lOOjil of Stop 
Solution was added to each well to stop the TMB reaction. The plate was read at 
wavelength 450nm with a microplate reader. 
2.3.4 Statistical Analysis 
For comparison of the means of two or more data groups, one-way ANOVA was 
performed and Tukey's Multiple Comparison Test was applied as the post hoc test. 
For comparison of the means of two dependent groups (control and drug-treated 
samples), paired t-test was performed. 
Data would be considered as statistical significant when p value is smaller than 0.05. 
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2.4 Results 
2.4.1 Dose-response and time-response study of LC978 in K562 by TMB assay 
To determine the maximum dosage of LC978 that could be used to induce fetal 
hemoglobin in K562 without causing cytotoxicity, two-fold serial dilutions of LC978, 
from lOOng/ml to 0.0489ng/ml, were performed and hemoglobin production was 
measured by TMB Assay for eight consecutive days as described in Methods 2.3.1. 
The TMB Assay measured the total hemoglobin content. A standard curve was 
established using Hemoglobin A2 and the cellular hemoglobin contents were 
measured from the standard curve. 
Over an eight-day period, the hemoglobin levels at each dilution of LC978, 
hydroxyurea were measured and results were plotted (Figure 2-1 and Figure 2-2). At 
the first two days, the hemoglobin levels were low. The hemoglobin content rose 
significantly at Day 3 and Day 4 and continued to increase and peaked at Day 7. Thus, 
a 7-day induction was chosen to be the appropriate time for maximal hemoglobin 
production. Maximum response concentrations of LC978 and hydroxyurea were 
3.125ng/ml (Figure 2-1) and 25|4.g/ml (Figure 2-2) respectively. Although 12.5ng/ml 
of hydroxyurea induced more hemoglobin than that with 25|a,g/ml of hydroxyurea on 
Day 7 (Figure 2-2), it exhibited a sharp decrease in hemoglobin induction on Day 8 
making it a less preferable dose as the induction efficiency dropped when the 
induction time could not be kept strictly. 25^ig/ml of hydroxyurea provided a more 
consistent hemoglobin induction and thus this dose was chosen to be a more 
reasonable dose for induction. 
The dose-response assay was performed as Xing described (Xing, 2003) and 
dose-response curves on Day 7 for LC978 and hydroxyurea were plotted (Figure 2-3). 
The ED50 of LC978 was 2.431ng/ml and that of hydroxyurea was 2.895|ig/ml which 
indicated a much lower dose of LC978 could be used to achieve 50% of maximal 
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hemoglobin induction than that of hydroxyurea. The ED50 obtained was deviated 
from Xing's work. Such deviation arose possibly because of different K562 cell 
clones. Clonal variation would result in drug response deviation. Statistical analysis 
by one-way ANOVA was performed on the hemoglobin levels of the negative control, 
25|j.g/ml hydroxyurea and 3.125ng/ml LC978 (Figure 2-4). Both hydroxyurea and 
LC978 showed a statistical significant difference in the hemoglobin induction when 
compared to the control (p< 0.001). In addition, the hemoglobin levels induced by 
hydroxyurea and LC978 have a statistical significant difference (p<0.001). 
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Hemoglobin Content in LC978-treated K562 
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Figure 2-1. The hemoglobin levels of LC978-treated K562. K562 cells were treated 
with various doses of LC978 for 8 consecutive days and total hemoglobin levels were 
measured by TMB staining assay every day. 
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Hemoglobin Content in Hydroxyurea-treated K562 
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Figure 2-2. The hemoglobin levels of hydroxyurea-treated K562. K562 cells were 
treated with various doses of hydroxyurea for 8 consecutive days and total 
hemoglobin levels were measured by TMB staining assay every day. 
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Dose-Response Curves of LC978 and Hydroxyurea (Normalized Data) 
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Figure 2-3. Dose-response curves of LC978 and hydroxyurea. K562 cells were treated 
with various doses of LC978 for 7 days and total hemoglobin was measured by TMB 
staining assay. The results were normalized and a dose-response curve was drafted 
through non-linear regression. The ED50 of LC978 and hydroxyurea was 2.431 ng/ml 
and 2.895|ig/ml respectively. 
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Control vs LC978 -4093 35.41 P < 0.001 
HU vs LC978 -2016 17.44 P < 0.001 
Figure 2-4. Hemoglobin levels of control, hydroxyurea- and LC978-treated K562 on 
Day 7. K562 cells were untreated or treated with 25|^g/ml of hydroxyurea and 
3.125ng/ml of LC978 for 7 days. Hemoglobin levels were measured by TMB staining 
assay and results were evaluated by one-way ANOVA. Tukey's Multiple Comparison 
Test was applied to determine how the mean of each treatment group differed from 
each other. 
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2.4.2 Detection of 7 -Globin Gene Expression in LC978-induced K562 by 
RT-PCR 
The TMB assay revealed the total hemoglobins induced by the drug. To study 
how 7 -globin gene expression was altered by LC978 induction at transcriptional 
level, semi-quantitative RT-PCR of the 7 -globin gene was performed. 
An increase in the mRNA level of the 7 -globin gene was observed in K562 
induced with 25|ig/ml of hydroxyurea and 3.125ng/ml of LC978 (Figure 2-5). 
Real-time PCR was performed and relative quantities of the copy number of the 
7 -globin cDNA was measured. Results were plotted in Figure 2-6 where data were 
expressed as ratio of the threshold cycle of 7 -globin gene under a particular 
condition to its corresponding threshold cycle of GAPDH. Both 25|a.g/ml of 
hydroxyurea and 3.125ng/ml of LC978 induced significant amount of 7 -globin 
mRNA (mean expressions in hydroxyurea-treated and LC978-treated K562 were 
0.963 and 1.000 respectively) when compared to the controls at Day 0 and Day 4 
(mean expressions at Day 0 and Day 4 were 0.451 and 0.216). However, the level of 
7 -globin mRNA in Day 4 control K562 was lower than that in Day 0 control K562. 
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Figure 2-5. Semi-quantitative RT-PCR of y -globin gene and GAPDH. RNA from 
uninduced K562, hydroxyurea-treated K562 and LC978-treated K562 were extracted 
and reverse transcribed to cDNA. The cDNA was then used as template for PCR as 
described in section 2.3.2.2. The sizes of the amplification product of j -globin gene 
and GAPDH would be 380bp and 452bp respectively. Lane M: 0.7|ag of Ikb Plus 
DNA Ladder; Lane 1: GAPDH, control K562 on Day 0; Lane 2: GAPDH, control 
K562 on Day 4; Lane 3: GAPDH, hydroxyurea-treated K562 on Day 4; Lane 4: 
GAPDH, LC978-treated K562 on Day 4; Lane 5: r -globin, control K562 on Day 0; 
Lane 6: j -globin, control K562 on Day 4; Lane 7: y -globin, hydroxyurea-treated 
K562 on Day 4; and Lane 8: r -globin, LC978-treated K562 on Day 4. 
Hydroxyurea-treated (Lane 7) and LC978-treated (Lane 8) K562 induced expression 
of 7 -globin significantly. 
46 
1.20-1 
0 1 .�� - j ^ 
1 0 . 8 0 - … 
in � 
^ 0.60 - � . � * --
夸 0.40 - 丨辩‘永：叫 ^ 
I p i 十 
0.00 丨 丨,:^1 M � � . " M 
‘ DayO Dav4 Day4 HU Day4 978 
control control 
Figure 2-6. Relative quantity of 7 -globin mRNA upon different conditions. RNA 
from uninduced K562, hydroxyurea-treated K562 and LC978-treated K562 were 
extracted and reverse transcribed to cDNA. The cDNA was then used as template for 
real time PGR using 7 -globin gene primers MF514 and MF515. Data were analyzed 
with iQ5 Gene Expression Software. The relative quantity of the 7 -globin mRNA 
was normalized to its GAPDH level. Results were expressed as the ratio of the 
threshold cycle of 7 -globin mRNA in a particular treatment to its corresponding 
threshold cycle of GAPDH and the ratio of 7 -globin to GAPDH in LC978-treated 
K562 on Day 4 was taken as 1.00. 
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2.4.3 Fetal Hemoglobin Analysis by Human Fetal Hemoglobin (HbF) ELISA 
Quantitation Kit 
Ability of LC978 to induce specifically fetal hemoglobin was determined by 
HbF ELISA. Serial dilutions ranged from lOOng/ml to 0.0489ng/ml of LC978 were 
used to treat K562 for 7 days and cellular proteins were extracted for HbF ELISA as 
described in Methods 2.3.3. 
A hemoglobin standard curve was constructed and the fetal hemoglobin levels 
were determined from the standard curve. 
The amount of fetal hemoglobin induced at different concentrations of LC978 
was measured (Figure 2-7). 3.125ng/ml of LC978 induced the largest amount of fetal 
hemoglobin which was 4 folds more than that of the negative control. Statistical 
analysis by student's paired t-test was performed on the fetal hemoglobin level of 
uninduced K562 and that ofK562 treated with 3.125ng/ml LC978 (Figure 2-8). There 
was statistical significant difference between uninduced and induced K562 (p< 0.05). 
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Figure 2-7. Fetal hemoglobin levels of LC978-treated K562. K562 cells were treated 
with various doses of LC978 for 7 days and the cellular fetal hemoglobin was 
measured by Human Fetal Hemoglobin ELISA Quantitation Kit. A dose-response 
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Figure 2-8. Statistical analysis of the fetal hemoglobin levels of the control and 
3.125ng/ml LC978-treated K562. Paired t-test was used to determine if the means of 
the fetal hemoglobin concentration of the control and LC978-treated groups differ 




2.5.1 Dose-response and time-response study of LC978 in K562 by TMB assay 
K562 cells were treated with LC978 (ranged from lOOng/ml to 0.0488ng/ml) and 
hydroxyurea (ranged from 100)j.g/ml to 0.0488|ig/ml) for 8 consecutive days and total 
hemoglobin was measured by TMB staining assay. 
At high concentration of LC978 and hydroxyurea, total hemoglobin 
concentrations measured were low because of the cytotoxic effect exerted by high 
doses of drugs. The optimal concentration for maximal hemoglobin induction 
occurred when the drug was not cytotoxic to the cells and fully occupied all the drug 
receptors to mediate an ample response. This concentration was determined to be 
3.125ng/ml of LC978 and 25jig/ml of hydroxyurea. When the optimal concentration 
was bypassed, the total hemoglobin dwindled even the concentration of the drug used 
was not cytotoxic because the drug receptors were not fully occupied when the drugs 
were diluted. Hence the hemoglobin induction ability of the drugs diminished at lower 
concentrations of the drugs. 
The amount of hemoglobin induced differed even both hydroxyurea and LC978 
were used at their optimal concentrations. 3.125ng/ml of LC978 was able to induce 
more hemoglobin than 25|ig/ml of hydroxyurea. It might be possibly due to the 
growth inhibition of K562 caused by hydroxyurea which reduced the total population 
of hemoglobin producing cells. 
For untreated K562, there was an increase in the hemoglobin content over days. 
K562 cells would produce a cytokine called erythropoietin (EPO) (Fraser et al., 1988). 
EPO is an essential factor that promotes growth and differentiation of immature 
erythroblasts through its interaction with the cell surface erythropoietin receptor 
(EPO-R) (Liboi et al., 1993). At high cell density, more erythropoietin accumulated 
in the culture medium which led to the auto-differentiation of the cells to produce 
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more hemoglobin. Thus hemoglobin hoarded up when the cell population grew. 
The time course study of hemoglobin induction provided some insight on the 
mode of LC978 action. There was barely an increase in hemoglobin content after the 
drugs were added. The hemoglobin levels remained low on the first two days 
implicating that LC978 was not likely to induce hemoglobin directly through 
translational machinery. If LC978 was able to accelerate the rate of translation of 
existing globin mRNA, there should be an increase in hemoglobin measured within a 
short period of time. However, our data repudiated this assumption and suggested that 
LC978 acted through transcriptional regulation. 
A 7-day drug treatment yielded the maximum amount of hemoglobin and 
prolonging the treatment time, on the other hand, did not further augment the amount 
of hemoglobin induced because prolonged drug treatment might start to impose a 
cytotoxic effect or the cells were depleted of nutrients and died. 
2.4.2 Detection of 7 -Globin Gene Expression in LC978-induced K562 by 
RT-PCR 
In real time RT-PCR, we expected the levels of 7 -globin mRNA in the control 
K562 on Day 0 and Day 4 would be very similar but it was found that 7 -globin 
mRNA in Day 0 was higher than that in Day 4. One possible reason for such 
observation was the difference in the cell density at Day 0 and Day 4. The cell density 
at Day 0 was higher than that at Day 4 and high cell density would speed the 
auto-differentiation of K562 and thus control K562 at Day 0 would produce more 7 
-globin mRNA. Since only a tiny portion of Day 0 control K562 was used to seed 
cultures for Day 4 experiment, the chance of passing differentiated K562 to new 
cultures was low. Perhaps in Day 4 control K562 culture, most of the cells seeded 
were still undifferentiated giving a low background 7 -globin mRNA level. 
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2.5.3 Fetal Hemoglobin Analysis by Human Fetal Hemoglobin (HbF) ELISA 
Quantitation Kit 
TMB assay was a quick and cost-effective method to determine the time- and 
dose-responses of LC978, but the assay only measured the total hemoglobin. Our 
emphasis on LC978 was its ability in inducing specifically fetal hemoglobin and so 
assay which measured fetal hemoglobin content was needed and human HbF ELISA 
was used. 
Analysis of the total hemoglobin by TMB assay and fetal hemoglobin by HbF 
ELISA in K562 on the day after induction showed consistent results: 3.125ng/ml 
of LC978 induced the largest amount of total hemoglobin and fetal hemoglobin. This 
could be explained by the fact that K562 itself exhibited embryonic/ fetal phenotype 
and upon addition of inducing agent, the cells would synthesize more embryonic and 
fetal hemoglobin (Rutherford et al., 1981). 
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Chapter 3 Signal Transduction Pathways Modulated by LC978 
3.1 Introduction 
Cells are living in a complex environment and communicating with other cells 
to guide their behavior and facilitate transport. Cell-to-cell communication allows 
transports of materials, for example, transmission of electrical signal via 
neurotransmitters across synapses, or alternation of cellular behavior such as the 
case of the endocrine cells. 
The extracellular matrix surrounding the cells actually contains a large of pool 
of chemicals and molecules that govern the survival, division, differentiation and 
death of cells. How these external signals are conveyed to intracellular message to 
change its cellular machinery? The movement of signals, at molecular level, from 
outside the cell to inside is referred to signal transduction. It describes a chain of 
molecular events that involve: 
1. Arrival of the external signals. 
2. Interaction of the signaling molecule with the cell-surface receptor. 
3. Change in receptor conformation and activity leading to activation of 
downstream proteins to propagate the signals inside the cells or even to the 
nucleus 
4. Modification of cellular activity and gene expression pattern to elicit a 
functional response. 
Cell surface receptors can be broadly classified into three main categories: 
receptors with intrinsic enzyme activities like the insulin receptor (Taniguchi et al., 
2006)，receptors coupled with GTP-binding and hydrolyzing proteins (G-proteins) 
like the adrenergic receptor (Johnson, 2006) and ligand-gated ion channel like the 
nicotinic acetylcholine receptor (Hogg et al，2005). 
Depending on the nature of the external signals, sometimes they may not 
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directly interact with the cell-surface receptors. They can pass through the cell 
membrane and bind with intracellular receptor and the receptor-ligand complex then 
translocates to the nucleus and alters gene transcription. One example is the steroid 
hormone receptor (Drummond, 2006). The hormone receptor resides in cytoplasm 
and binds with lipophilic steroid hormone. After binding with the hormone, the 
receptor-hormone complex translocates to the nucleus and binds to specific DNA 
sequence called the hormone response elements which alters the rate of gene 
transcription of a particular gene. 
There are numerous types of signaling molecules and hence the types of 
receptors. However, each cell type, under a particular cellular environment, only 
possesses a certain set of receptors and/ or different transduction molecules. So 
different cells will respond differently to different stimulus or same stimulus. For 
instance, the neurotransmitter acetylcholine stimulates skeletal muscle contraction 
while decreases rate of heart muscle contraction (Taylor and Brown, 1999). To study 
which pathways are turned on or off in response to a particular stimulus, we can 
observe these changes at RNA (mRNA) or protein level. 
One of the widely used methods to study signal transduction pathway by 
measuring differential gene expression is DNA microarray. With the use of 
microarray, large-scale analysis of gene expression can be performed with high 
density DNA microarray in a relatively short time. Fabrication of DNA microarray 
refers to the spotting of DNA onto a piece of nylon membrane or glass slide by 
pin-spotting robot or ink jet printer. The DNA spotted comes from genomic DNA, 
cDNA, PGR products or chemically synthesized oligonucleotides. After choosing 
the suitable DNA microarray, RNA from tissues or cells are extracted and reverse 
transcribed to give cDNA and during reverse transcription, the cDNA will be 
"tagged". The tags used depend on the method of detection, they can be radioactive, 
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fluorescent and chemiluminescent. The cDNA will then be hybridized with the 
target DNA and the signal of the probe-target duplex will be measured by an 
appropriate instrument. 
Only changes in the transcription level which affects the quantity of the mRNA 
of a particular gene can be measured by DNA microarray. How can DNA microarray 
be used to detect the activation or repression of different signal transduction 
pathways? As mentioned earlier, the signaling components carry the message from 
the exterior to the interior by a cascade of kinases and the final destination of the 
external signals will eventually be conveyed to the nucleus. Transcription factors 
which contain DNA-binding motif are responsible for relaying the message from the 
cytoplasm to nuclear DNA, where their DNA-binding motif will bind to DNA in a 
sequence specific manner and alter gene transcription by interacting with RNA 
polymerase. 
Oligo GEArray® Human Oligo Signal Transduction PathwayFinder Microarray 
is imprinted with 113 marker genes which represent 18 signal transduction pathways. 
These marker genes are downstream effectors or target genes that respond to the 
signal of a particular pathway. These genes are subjected to transcriptional 
regulation - the changes in mRNA level, upon receiving appropriate signals. 
The objectives of this part of the project were to screen for pathways that were 




3.2.1 Chemicals and Reagents 
Chemical/ Reagent Source, Catalog Number 
RPMI Medium 1640, powder Gibco 23400-021 
Sodium Bicarbonate (NaHCOs), Cell Culture Tested Sigma S5761 
Fetal Bovine Serum, Qualified Gibco 10270-106 
Antibiotic-Antimycotic (1OOX), liquid Gibco 15240-062 
LC978, lO^ig/ml 
TRIzol® Reagent Invitrogen 15596-018 
Chloroform, Analytical Reagent LabScan 
Isopropanol Merck 100994 
Absolute Ethanol, ACS Grade Merck 100983 
Sodium Acetate Sigma S2889 
Acetic Acid Merck 818755 
Sodium Chloride (NaCl) RDH 31434 
Sodium Citrate Dihydrate Sigma W302600 
Sodium Dodecyl sulfate (SDS) Sigma L5750 
Biotin-16-uridine-5‘-triphosphate (Biotin-16-UTP) Roche 11-388-908-910 
3.2.2 Kits 
Kit Source, Catalog Number 
A r r a y G r a d e ™ Total RNA Isolation Kit Super Array GA-013 
TrueLabeling-AMP™ 2.0 SuperArray GA-030 
ArrayGrade™ cRNA Cleanup Kit SuperArray GA-012 
GEAhyb Hybridization Solution SuperArray H-01 
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Chemiluminescent Detection Kit SuperAiray D-01 
Oligo GEArray® Human Oligo Signal Transduction 
… 广 」 、 灰 . Super Array OHS-014 PathwayFinder Microarray 
M-MLV Reverse Transcriptase, 200U/^1 (with 5X 
First Strand Buffer &0.1MDTT) Invitrogen 28025-013 
iQ™ SYBR Green Supermix BioRad 170-8880 
3.2.3 Buffers and Solutions 
Buffer/ Solution Preparation 
1 pack of RPMI Medium 1640 powder and 
2.0g sodium bicarbonate was added to 950ml 
Milli-Q H2O. The pH of the mixture was 
RPMI Medium 1640 adjusted with IM NaOH to pH 7.2. Milli-Q 
(2.05mM L-glutamine, 25mM H2O was added to make up the medium to IL. 
HEPES Buffer and 0.02M The medium was then filtered through 0.22|im 
NaHCOs) filter. 
Complete RPMI was prepared by adding FBS 
and PSF at final concentrations of 10% and 1% 
respectively. 
Absolute ethanol was added to DEPC-treated 
RNase-free 70% Ethanol ^ , . 
H2O to a final concentration of 70% (v/v). 
7.38g of sodium acetate was dissolved in 20ml 
DEPC-treated H2O. The pH of the solution was 
3M Sodium Acetate, pH 5.2 adjusted with acetic acid to pH 5.2. DEPC-H2O 
was added to make up the solution to 30ml. The 
solution was autoclaved. 
43.825g of NaCl and 22.05g of sodium citrate 
20XSSC dehydrate were dissolved in 200ml Milli-Q 
(3M NaCl and 0.3M sodium H2O. The pH of the solution was adjusted with 
citrate), pH 7.0 HCl to pH 7.0. Milli-Q H2O was added to make 
up the solution to 250ml. 
20g of SDS was dissolved in 100ml Milli-Q 
20% SDS (w/v) TT ^ 
H2O. 
Wash Solution 1 (2X SSC, 1% 10ml of 20X SSC and 5ml of 20% SDS were 
SDS) added to 85ml of Milli-Q H2O. 
Wash Solution 2 (O.IX SSC, 0.5ml of 20X SSC and 2.5ml of 20% SDS were 
0.5% SDS) added to 97ml of Milli-Q H2O. 
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This buffer was freshly prepared. 5X Buffer F 
IX Buffer F was diluted with Milli-Q H2O by five-fold to 
IX Buffer F. 
The alkaline phosphatase-streptavidin (AP-SA) 
Dilute AP-SA Buffer 
was diluted at 1:8000 with IX Buffer F. 
3.2.4 Primers 
Reference Description/ Tm 
Code Sequence (°C) 
size (bp) 
Human GAPDH, upper primer 
MF214 ^^ ^ 62 
5’-ACC ACA GTC CAT GCC ATC AC-3' 
452 
Human GAPDH, lower primer 
MF215 ^ 62 
5,-TCC ACC ACC CTG TTG CTG TA-3' 
Human NGFI-A binding protein 2 (NAB2), upper 
ImF 1209 primer 62 
5，-ACA TCC TGC AGC AGA CAC TG-3’ 
200 
Human NGFI-A binding protein 2 (NAB2), lower 
'MF 1210 primer 60 
5，-CTC CAC TTT CAC GCT GCT C-3, 
Human v-jun sarcoma virus 17 oncogene homolog 
^MF 1211 (JUN), upper primer 74 
5'-CAT GGA GTC CCA GGA GCG GAT CA-3' 
； 248 
Human v-jun sarcoma virus 17 oncogene homolog 
^MF 1212 (JUN), lower primer 70 
5,-GCA ACT GCT GCG TTA GCA TGA GT-3， 
Human early growth response 1 (EGRl), upper 
IMF 1213 primer 60 
5，-CAG CAC CTT CAA CCC TCA G-3' 
201 
Human early growth response 1 (EGRl), lower 
IMF 1214 primer 72 
5,-CAC AAG GTG TTG CCA CTG TT-3, 
, Human GAPDH, upper primer 
^MF 1217 ^^ ^ 72 
5’-TGG TAT CGT GGA AGG ACT CAT GAC-3, 189 
. Human GAPDH, lower primer 
^MF 1218 76 
5，-ATG CCA GTG AGC TTC CCG TTC AGC-3, 
(Primers were designed based on literature: 'Lucema et al, 2003; ^Shiramizu et al, 
2005; ^Grigolo et al, 2005) 
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3.2.5 Equipment and Other Consumables 
Equipment/ Consumables Source, Catalog Number 
Bench-top centrifuge Eppendorf 5415D 
Bench-top centrifuge (refrigerated) Eppendorf 5804R 
Thermal Cycler MJ Research PTC-200 
iQ5 Real-Time PGR Detection System BioRad 
Hybridization Oven Hybaid Mini 10 Oven 
Lumi-Imager F1 Workstation Roche Applied Science 
200^1 Thin Wall Tube Strips BioRad 223-9469 
0.2ml Thin Wall 8-Cap Strips BioRad 223-9472 
Hemacytometer Bright-Line 
RNaseZAP Sigma R2020 
ART® Aerosol Resistant Tips Molecular BioProducts 
3.2.6 Maintenance of K562 
The cultures were grown in Complete RPMI and maintained by sub-cultured in fresh 
medium when the cell density reached 2x10^ cells/ml. The cultures were incubated 
in 37°C humidified CO2 incubator with 95% air and 5% CO2. 
3.2.7 Handling and Treatment of utilities for RNA isolation 
All glassware and forceps were baked at 220 °C overnight before use. The 
microcentrifuge tubes were autoclaved. RNase-free H2O was prepared by treating 
Milli-Q H2O with 0.1% DEPC (v/v) for overnight. The bottle was inverted overnight 
and after that, the DEPC-H2O was autoclaved at 121°C for 20 minutes to remove 
DEPC. To avoid RNase contamination, the working area was cleaned by RNaseZAP 
and gloves were changed frequently. The pipette tips used for RNA work were 
sterile filtered tips. 
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3.3 Methods 
3.3.1 Identification of Signaling Pathways by Microarray 
3.3.1.1 Induction of K562 with LC978 
A 120ml K562 culture was grown to 2 x 10^  cells/ml. 30ml of this culture was 
collected in a 50ml falcon. For the remaining 90ml of culture, 28.13|al of 10|ig/ml 
LC978 was added to the culture such that the final concentration was 3.125ng/ml. 
The culture was then incubated in 37°C CO2 incubator. 30ml of the culture was 
collected at 3, 12 and 24 hours post-induction. 
3.3.1.2 Extraction of total RNA 
Cells collected from section 3.3.1 was centrifuged at 300 x g for 10 minutes (25°C) 
and the culture medium was removed. The cell pellet was then lysed with 1ml 
TRIzol Reagent. The lysate was incubated at room temperature for 5 minutes. The 
lysate could be kept at -70°C for further use. 
The lysate was centrifuged at 14,000rpm for 10 minutes (4°C) and the clear 
supernatant was transferred to a clean microcentrifuge tube. 200|j.l of chloroform 
was added and the tube was vortexed for 30 seconds. The mixture was incubated at 
room temperature for 3 minutes and was centrifuged at 14,000rpm for 10 minutes (4 
°C). After centrifugation, the uppermost clear supernatant was transferred to clean 
microcentrifuge tube. 500|xl of Isopropanol was added to the supernatant and the 
mixture was incubated at room temperature for 10 minutes. The tube was 
centrifuged at 14,000rpm for 10 minutes (4°C). Supernatant was removed carefully 
without disturbing the white RNA pellet. 1ml of RNase-free 70% ethanol was 
layered carefully over the pellet to wash away excess salts and the tube was 
centrifuged at 14,000rpm for 5 minutes (4°C). Supernatant was removed carefully 
without disturbing the white RNA pellet. The pellet was dried at room temperature. 
lOOiil of DEPC-treated H2O was added to dissolve the pellet. The RNA was 
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incubated at 65 °C for 10 minutes with intermittent vortexing to enhance complete 
dissolution. OD at 230, 260 and 280nm were taken to determine the concentration 
and purity of the RNA. 
3.3.1.3 Purification of total RNA using ArrayGrade^"^ Total RNA Isolation Kit 
50)0.1 of RNA was mixed with 350|j,l of Lysis & Binding Buffer. 350|il of RNase-free 
70% ethanol was added. All components were transferred to the spin column and 
centrifuged at 8,000 x g for 30 seconds. The flow-through was discarded and the 
column was washed with 350|xl of Desalting Buffer. The column was centrifuged at 
11,000 X g for 1 minute and flow-through was discarded. 200|il of Pre-Wash Buffer 
was added and the column was centrifuged at 8,000 x g for 30 seconds. 350|il of 
Washing Buffer (w/ ethanol) was added and the column was centrifuged at 8,000 x g 
for 30 seconds. The column was washed again with 200|il of Washing Buffer (w/ 
ethanol) and centrifuged at 11,000 x g for 3 minutes. The spin column was 
transferred to a clean, RNase-free microcentrifuge tube. 50)j.l of RNase-free H2O 
was added to the column and incubated at room temperature for 3 minutes. The 
column was centrifuged at 11,000 x g for 1 minute. OD at 230, 260 and 280nm were 
taken to determine the concentration and purity of the RNA. 
3.3.1.4 Ethanol Precipitation of RNA 
3M Sodium acetate and absolute ethanol were added to the purified RNA such that 
the volume of sodium acetate is 1/10 of the total volume of RNA while volume of 
absolute ethanol was 2.5 folds of the total volume of RNA. The contents were mixed 
well and incubated at -20°C for 30 minutes. The tube was centrifuged at 14,000rpm 
for 30 minutes (4°C). Supernatant was removed carefully without disturbing the 
white RNA pellet. 1ml of RNase-free 70% ethanol was layered carefully over the 
pellet to wash away excess salts and the tube was centrifuged at 14,000rpm for 5 
minutes (4°C). Supernatant was removed carefully without disturbing the white 
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RNA pellet. The pellet was dried at room temperature. 50|j,l of RNase-free H2O was 
added to dissolve the pellet. The RNA was incubated in 65°C for 10 minutes with 
intermittent vortexing to enhance complete dissolution. OD at 230, 260 and 280nm 
were taken to determine the concentration and purity of the RNA. 
3.3.1.5 cDNA Synthesis using TrueLabeling-AMP^^ 2.0 Kit 
In a microcentrifuge tube, 3|xg of RNA, 1.0|il of TrueLabeling Primer and 
RNase-free H2O were added to a final volume of 1 Ojil. The tube was incubated at 70 
°C for 10 minutes and chilled on ice immediately. To each tube, 4|il of RNase-free 
H2O, 4^1 of 5X cDNA Synthesis Buffer, l^il of RNase Inhibitor and l|xl of cDNA 
Synthesis Enzyme Mix were added. The mixture was incubated at 42°C for 50 
minutes followed by 75 °C for 5 minutes and cooled to 37°C. 
3.3.1.6 cRNA Synthesis using TrueLabeling-AMP^'^ 2.0 Kit 
To each 20^1 cDNA reaction, 16|al of 2.5X RNA Polymerase Buffer, 2 .^1 of 
Biotin-16-UTP and 2\i\ of RNA Polymerase Enzyme were added. The mixture was 
incubated at 37°C for 20 hours. 
3.3.1.7 cRNA Purification using ArrayGrade^"^ cRNA Cleanup Kit 
60|il of RNase-free H2O was added to each cRNA Synthesis reaction tube for a final 
volume of lOO i^l and the entire content was transferred to a clean, RNase-free 1.5ml 
microcentrifuge tube. The cRNA was mixed with 350^1 of Lysis & Binding Buffer. 
350|il of absolute ethanol was added. All contents were loaded onto the spin column 
and centrifiiged for 30 seconds for 8,000 x g. The flow-through was discarded and 
the column was washed with 600jil of Washing Buffer (w/ ethanol). The column was 
centrifuged at 8,000 x g for 30 seconds and flow-through was discarded. 200jal of 
Washing Buffer (w/ ethanol) was added to the column and the column was 
centrifuged at 11,000 x g for 3 minutes. The spin column was transferred to a clean, 
RNase-free microcentrifuge tube. 50|il of RNase-free lOmM Tris buffer pH 8.0 was 
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added to the column and incubated at room temperature for 3 minutes. The column 
was centrifuged at 8,000 x g for 1 minute. OD at 260nm was taken to determine the 
concentration and yield of the cRNA. 
3.3.1.8 Hybridization 
The GEAhyb Hybridization Solution was wanned to 60°C. The array membrane was 
pre-wetted with 5ml autoclaved Milli-Q H2O for 1 hour. Water was discarded and 
2ml of pre-warmed GEAhyb Hybridization Solution was added. The membrane was 
then pre-hybridized in hybridization oven at 60°C for 5 hours with continuous 
agitation at 7 rpm. 3|ig of cRNA was added to 0.75ml pre-warmed GEAhyb 
Hybridization Solution. The pre-hybridization solution was discarded. The 0.75ml 
hybridization mix containing cRNA was added to the hybridization tube. The 
membrane was hybridized at 60°C with continuous agitation at 7 rpm for 20 hours. 
The hybridization mix was removed and 5ml Wash Solution 1 was added. The tube 
was vortexed briefly and the membrane was washed at 60°C with faster agitation at 
15 rpm for 15 minutes. The Wash Solution 1 was discarded and replaced with 5ml 
Wash Solution 2. The tube was vortexed briefly and the membrane was washed at 60 
。C with faster agitation at 15 rpm for 15 minutes. The Wash Solution was discarded 
and the membrane was cooled to room temperature. 
3.3.1.9 Chemiluminescent Detection using Chemiluminescent Detection Kit 
2ml of GEAblocking Solution Q was added to the hybridization tube. The tube was 
vortexed briefly and incubated at 25°C with continuous agitation at 15 rpm for 40 
minutes. The GEAblocking Solution Q was discarded. 2ml of Dilute AP-SA Buffer 
was added. The tube was vortexed briefly and incubated at 25 °C with continuous 
agitation at 7 rpm for 10 minutes. The Dilute AP-SA Buffer was discarded. The 
membrane was washed four times with 4ml of IX Buffer F for 5 minutes with 
agitation at 7 rpm. The membrane was rinsed (by inverting the tube few times) twice 
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with 3ml of Buffer G. Buffer G was discarded and 1ml of CDP-Star 
chemiluminescent substrate was added to each tube. The membrane was incubated 
at 25°C with continuous agitation at 7 rpm for 5 minutes. The membrane was taken 
out from the hybridization tube with forceps and dripped away excess liquid. The 
membrane was placed into a small plastic zip-lock bag and bubbles were smoothed 
out. The image was captured with a cooled CCD camera of the Lumi-Imager F1 
Worksatation with exposure time at 1 minute. 
3.3.1.10 Data Analysis 
The raw images obtained from 3.3.1.9 were analyzed with the software GEArray 
Expression Analysis Suite. Data were normalized with GAPDH. 
3.3.2 Real-time RT-PCR 
3.3.2.1 Induction of K562 with LC978 
K562 cells were treated as described in section 3.3.1.1. 
3.3.2.2 Extraction of total RNA 
Total RNA of the cells collected in 3.3.2.1 were extracted as described in section 
3.3.1.2. 
3.3.2.3 Genomic DNA Contamination Check by PGR 
For 25-|xI PGR reaction, the followings were added to a microcentrifuge tube: 0.1 |ig 
of RNA, 2.5^1 of lOX PGR Reaction Buffer, 1.5^1 of 25mM magnesium chloride 
(MgCb), 0.5^1 of lOmM dNTP Mix, 0.5^1 of 25nM MF214, 0.5^1 of 25nM MF215, 
0.1 |il of Taq DNA polymerase (5U/|LI1) and autoclaved Milli-Q H2O was added to 
make up the reaction volume to 25|il. The reaction was performed in a Thermal 
Cycler with initial denaturation at 96°C for 4 minutes. 40 cycles were repeated with 
denaturation at 96°C for 30 seconds, annealing at 60°C for 30 seconds and 
extension at 72°C for 30 seconds. A final extension step at 72°C for 5 minutes was 
added and the reaction was cooled to 4�C. 
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The PGR products were separated on 1% agarose gel at lOOV till the tracking dye 
reached 2/3 of the gel cast. 
3.3.2.4 Reverse Transcription 
For 20-|il reaction volume, Ijil of 1 |J.g/|J.l oligo (dT)i2-i8, l|ig of RNA, l|il of lOmM 
dNTP Mix and DEPC-treated H2O were added to 12|j1 The mixture was heated at 
65°C for 5 minutes and chilled on ice immediately. 4jLil of 5X First Strand Buffer, 
2|il of O.IM DTT and \\i\ of 40units/^l RNaseOUT Recombinant Ribonuclease 
Inhibitor were added to the mixture which was then incubated in 37°C for 2 minutes. 
1 |il (200 units) of M-MLV RT were added to each tube by pipetting up and down. 
The final mixture was incubated in 37 °C for 60 minutes. The reaction was 
inactivated by heating at 70°C for 15 minutes. 
3.3.2.5 Real-time PGR 
Each 20)li1 RT reaction was diluted in 80|j,l of Milli-Q H2O. The cDNA was boiled 
for 15 minutes and chilled on ice immediately. The PGR reaction was set by adding 
25|j,l of 2X iQ SYBR Green Supermix, \[d of 25pmole/|il Forward Primer, l|il of 
25pmole/|xl Reverse Primer, 18|j.l of autoclaved Milli-Q H2O and 5|al of diluted 
cDNA. 5|il of Milli-Q H2O was used instead of cDNA as the No Template Control 
(NTC) to determine the background fluorescence of the reagents. 
The PCR reaction was started with an initial activation step at 95°C for 3 minutes. 
40 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds 
and extension at 72°C for 30 seconds were repeated. After PCR, a melt curve 
analysis was performed. The whole reaction was cooled to 55°C and temperature 
was increased by 0.2°C per second until it reached 95°C. The occurrence of a single 
large peak indicated the PCR was highly specific. Data were analyzed by the iQ5 
software according to manufacturer's instruction. The relative quantity of the target 
gene was normalized to the relative quantity of the reference gene GAPDH. 
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3.4 Results 
3.4.1 Identification of Signaling Pathways by Microarray 
The Oligo GEArray® Human Signal Transduction PathwayFinder^'^ 
Microarray contained genes representing 18 different signal transduction pathways: 
mitogenic pathway, Wnt pathway, Hedgehog pathway, TGF-p pathway, survival 
pathway, p53 pathway, stress pathway, NFKB pathway, NFAT pathway, C R E B 
pathway, JAk-Stat pathway, estrogen pathway, androgen pathway, phospholipase C 
pathway, calcium and protein kinase C pathway, insulin pathway, LDL pathway and 
retinoic acid pathway. 
K562 cells were treated with 3.125ng/ml of LC978 and induced for 3, 12 and 
24 hours respectively. Uninduced cells were used as control. Total RNA for the cells 
at each time point was extracted and purified. cRNA was synthesized and hybridized 
with the oligo microarray. The array layout was shown in Figure 3-1. Raw images 
were taken (Figure 3-2) and were analyzed with the software GEArray Expression 
Analysis Suite. Signal intensities of the microarrays were normalized with the 
housekeeping gene GAPDH. The relative gene expression changes were calculated 
as the ratio of the normalized signal intensity of a particular gene at time point 3, 12 
or 24 hour to the normalized signal intensity of that gene at control (time 0). 
Genes with expression changes, relative to control, for more than 2 folds were 
tabulated (Table 3-1). These genes belonged to the mitogenic pathway, stress 
pathway, p53 pathway, calcium and protein kinase C pathway and survival pathway. 
Since each pathway had different number of representative genes, the hit percentage 
of each pathway was determined. The hit percentage was calculated as the number 
of genes, in a particular pathway, with expression level change for more than 2 folds 
over the total number of representative genes in that pathway. The pathway which 
scored the highest hit percentage would be chosen for further study (Table 3-2). The 
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mitogenic pathway had the highest hit percentage (75%) and was believed to be the 
major pathway modulated by LC978. 
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Figure 3-1. Layout of the Oligo GEArray® Human Signal Transduction 
PathwayFinder™ Microarray. 
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Figure 3-2. Microarray images captured at 1-minute exposure using a cooled CCD 
camera system. K562 cells were treated with 3.125ng/ml of LC978 for 3,12 and 24 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3-2. Functional grouping of the differentially expressed genes. 
Genes with expression level change . . 
Signal transduction pathway Hit % 
for more than 2 folds 
EGRl, JUN, NAB2 Mitogenic Pathway 75% 
ATF2, HSFl, HSPCA, MYC Stress Pathway 57% 
CDKNIA, GADD45A, TNFRSFIOB, 
p53 Pathway 50% 
TP53I3 
Calcium & Protein Kinase C 
IL2, JUN, MYC, ODCl, TFRC 45.5% 
Pathway 
FNl, JUN, MYC, BCL2L1，BIRC3 Survival Pathway 38.5% 
Footnote: Genes with expression level change for more than 2 folds were organized in 
the pathways they belonged to. The relevance of a signal transduction pathway 
modulated by LC978 was expressed as the hit percentage. 
Hit % = number of genes with expression level change >2 folds ^ 湖。/。 
total no. of representative genes in that pathway 
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3.4.2 Real-time RT-PCR 
To validate the gene expression data obtained from microarray analysis, real-time 
RT-PCR was performed. Three genes of the mitogenic pathway had shown differential 
expression at different time points of LC978 treatment using microarray, they were 
EGRl, JUN and NAB2. Primers were designed for each gene based on previous 
research papers used for SYBR Green real-time PGR quantitation (refer to section 
3.2.4 for references). 
Quality of the RNA was checked before reverse transcription and real-time 
analysis. To check for the presence of genomic DNA contamination in the RNA, PCR 
using RNA and GAPDH primers was performed. No amplification products were 
detected by agarose gel electrophoresis which indicated the purity of RNA extracted 
(Figure 3-3). 
Real-time PCR was performed as described in section 3.3.2.4. The amplification 
chart showed the changes in the intensity of fluorescence during the ^CR reaction and 
hence allowed us to determine the threshold cycle (CT). In order to check the 
specificity of the real-time PCR reaction, a melt curve analysis was run immediately 
after the PCR was finished. A single large peak which occurred at temperature beyond 
80°C indicated the specificity of the primers used in the reaction. Since for each set of 
real-time PCR experiment the target gene and reference housekeeping gene would be 
run together, each melt curve graph would show two distinct large peaks representing 
the PCR products of the target gene and the housekeeping gene GAPDH respectively. 
The amplification charts and melt curves for EGRl, JUN and NAB2 were shown 
in Figure 3-4. The melt curves of EGRl and JUN showed the specificity of each 
real-time PCR reaction. The two peaks in each of the melt curve graph represented the 
PCR products of the target gene and GAPDH respectively. However, for NAB2, the 
melt curve graph showed one large peak, which represented the amplification product 
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of GAPDH, and two smaller peaks. These small peaks were from NAB2 amplification 
which might reflect there was a mixture of primer-dimer, non-specific amplification 
products and amplification products of NAB2. The primers for NAB2 were 
previously tested for specificity using traditional PCR (25|il-reaction; 95°C for 30 
seconds, 60�C for 30 seconds and 72°C for 30 seconds; 40 cycles). A single band of 
200 base pairs without any primer-dimer formation was detected. So, it was not 
known why real-time analysis gave such unexpected results. 
The expression of the target gene at different time points was normalized to 
corresponding expression of GAPDH. The normalized gene expression was computed 
and shown in Figure 3-5. All genes displayed the same expression pattern: they were 
all up-regulated after 3 hours of post-induction and resumed to background level 
beyond 12 hours of post-induction. 
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Figure 3-3. Determination of quality of RNA extracted for reverse transcription and 
real time PCR. PCR was set using RNA as template and used to amplify GAPDH for 
40 cycles. Amplified products were separated on 1% agarose gel and no bands were 
detected indicating the RNA extracted was free of genomic DNA. Lane M: 0.7|a,g of 
Ikb Plus DNA Ladder; Lane 1: RNA from control K562; Lane 2: RNA from K562 
induced with LC978 for 3 hours; Lane 3: RNA from K562 induced with LC978 for 12 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5.1 Identification of Signaling Pathways by Microarray 
DNA microarray has emerged as an efficient tool for analyzing expression of 
mass number of genes at one time. Commonly used microarray platforms are cDNA 
microarray and oligonucleotide-based microarray. The two arrays are used in RNA 
expression analysis but oligonucleotide array can also be used in sequence analysis 
(Stears et al, 2003). 
Oligonucleotide-based microarray is more preferable than cDNA microarray. 
The length of the cDNA probes are usually of 100-200 base pairs and reliable 
mismatch controls have to be generate to assess the hybridization specificity. The 
development of oligonucleotide-based microarray offers a number of advantages 
over cDNA microarray. The higher specificity of oligonucleotides in hybridization 
provides researchers a useful tool in detecting single nucleotide polymorphism 
(LaForge et al, 2000) and gene mutations (Hacia and Collins, 1999). In addition, it 
also allows us to address questions on the transcriptome such as the presence of 
alternatively spliced variants (Hu et al.’ 2001). Oligonucleotide-based microarray 
has a larger capacity for screening the whole genome and discovery of a new gene 
(Hughes and Shoemaker, 2001). It would be also easier for making an 
oligonucleotide-based microarray because only sequence information is needed for 
constructing such array. 
The purpose of this part of the project was to identify signal transduction 
pathways modulated by LC978 and therefore, a DNA chip, if possible, containing a 
large number of genes representing different signal transduction components should 
be used. Affymetrix offers Human Genome Array with more than 10,000 genes 
printed on one array. This kind of high-density array allows us to fully analyze the 
gene expression upon LC978 addition at a genome-wide scale, however, the cost of 
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such array is much higher. More economical way of microarray analysis is using 
focused microarrays. These arrays only contain genes of a particular pathway or 
representative genes of different pathways like the Oligo GEArray® Human Oligo 
Signal Transduction PathwayFinder Microarray. 
Since we were analyzing two samples, control and LC978-treated K562, two 
microarray formats could be used - single-color and dual-color. In single-color 
analysis, each sample is tagged with one label and the expression profiles of 
different samples are compared among different arrays. While in dual-color analysis, 
two samples can be labeled with two different fluorescent dyes and hybridized on 
the same chip. Intensity of the two fluorescent dyes on a gene shows the difference 
of the expression of that gene under two conditions. The single-color analysis would 
introduce more variations as each hybridization is done individually even 
chip-to-chip variations could be minimized by purchasing the same batch of 
microarrays. The Super Array's Oligo GEArray® Human Oligo Signal Transduction 
PathwayFinder Microarray only supported single-color detection and chip-to-chip 
variation was minimized by (i) purchasing the same batch of microarrays of each set 
of the experiment; (ii) using the same set of reagents for each set of the experiment; 
and (iii) performing all hybridizations at one time. 
To increase the reliability of the microarray data, the microarray experiment 
should be performed at least in replicate. Due to the limited reagents and high cost 
of each experiment, the experiment could only be repeated once. The absolute 
intensity of the signals from the two sets of microarray experiments varied in a great 
extent but the expression patterns were conserved. 
Pathways evaluated based on gene transcriptional activity are sometime 
misleading. Downstream target genes are seldom regulated by a single signal 
transduction pathway. Different pathways may act to control the same target gene. 
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Thus, DNA microarray is not specific enough to reflect on the specificity of the 
incoming signal. 
The mitogenic pathway, also known as mitogen-activated protein kinase 
(MAPK) pathway, remained as the primary pathway modulated by LC978. The 
relationship of MAPK and fetal hemoglobin induction had been extensively studied 
and details would be discussed in the next chapter. 
3.5.2 Real-time RT-PCR 
To eliminate the false-positive data in microarray, real-time RT-PCR on NAB2, 
JUN and EGRl was performed. All three genes were up-regulated by LC978 after 
3-hour of induction and resumed to background level afterwards. 
The JUN protein was originally identified as an oncoprotein encoded by an 
insert in the viral genome of avian sarcoma virus 17 and thus it was named v-JUN 
(Maki et al.，1987). JUN proteins contain a N-terminal JNK docking domain (delta 
domain) adjacent to the JNK phosphorylating site. In the C-terminal, there is a basic 
domain for DNA binding, followed by a nuclear localization signal (NLS) and a 
leucine zipper motif for dimerization with partner proteins. JUN is a critical 
component of AP-1 transcription factor that recognizes the palindromic DNA 
sequence TGAC/GTCA in the promoter and intron regions of a number of genes. It 
can homodimerize and heterodimerize with Fos protein to form AP-1 complex. In 
addition, JUN can also interact with some activating transcription factor (ATF) 
members, such as ATF2, ATF3 and ATF4, to form heterodimers that bind to the 
cAMP-responsive element (CRE) DNA sequence, TGACGTCA. As a member of 
the MAPK pathway, JUN regulates cell proliferation by promoting cell cycle 
progression, apoptosis and transformation (Vogt, 2001). 
The early growth response 1 (EGR-1) gene, also known as zif268, nerve 
growth factor induced (NGFI)-A, Krox24 and TIS8, is a zinc finger transcription 
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factor which is induced upon exposure to a variety of stimuli like growth factors and 
hormones. The EGR-1 protein contains a DNA-binding domain, activation domain 
and inhibitory domain (Thiel et al, 2000). The induction of EGR-1 gene by growth 
factor suggested the role of extracellular signal regulated protein kinase (ERK) 
pathway in triggering EGR-1 gene transcription. It was found that constitutive 
expression of MEKl, which was the upstream activator of ERK, enhanced the 
EGR-1 promoter activity and hence EGR-1 mRNA level. Apart from regulating 
EGR-1 transcription, ERK also increased the activity of EGR-1 proteins to activate 
transcription of other target genes (Kaufamann et al, 2001). 
NAB proteins were first identified as EGR-1 binding protein and NAB2 was 
later identified as a nuclear protein overexpressed in human malignant melanoma. 
NAB2 is induced by the same environmental stimuli that lead to EGR-1 expression. 
EGR-1 is an immediate early response gene while NAB2 is a delayed early response 
gene which implies the importance of NAB2 as a regulator of EGR-1 expression. 
NAB2 binds to the inhibitory domain on the EGR-1 protein and inhibits EGR-1 
activity. EGR-1 increased the promoter activity of NAB2 and the increased NAB2 
expression in turn repressed EGR-1 activity. This kind of regulation was important 
because it prevented permanent activation of ERG-1 target genes and over-reaction to 
environmental stimulus (Kumbrink et al., 2005). Our results also demonstrated an 
increase in EGRl expression was accompanied by a corresponding surge in NAB2 
expression and this also explained why EGRl expression dropped after reaching peak 
expression at 3 hour of post-induction. 
Up-regulation of JUN, EGRl and NAB2 expression indicates LC978 may 
stimulate the K562 cells and transduce signals through the mitogenic signal 
transduction pathway. 
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Chapter 4 MAPK pathways and HbF induction by LC978 
4.1 Introduction 
The mitogen-activated protein kinase (MAPK) participates in regulation of many 
fundamental cellular processes (Pearson et al., 2001). The MAPK signaling pathway 
transduces mitogenic signals and cellular stress to appropriate responses and this 
pathway is mainly involved in cell proliferation, differentiation and survival (Cobb, 
1999). 
MAPKs are serine/threonine protein kinases. They recognize the amino acid 
sequence Thr-Xaa-Tyr and phosphorylate on both the threonine and tyrosine residues. 
MAPK activity is regulated through a cascade composed of three central elements: a 
MAPK kinase kinase (MAPKKK or MEKK) which phosphorylates the MAPK kinase 
(MAPKK, MKK or MEK); and MAPKK in turn phosphorylates downstream MAPK. 
The activated MAPK can phosphorylate transcription factors and other protein 
kinases (Chang and Karin, 2001). 
Three distinct subgroups within the MAPK family have been described -
extracellular signal-regulated kinases (ERKs), c-jun N-terminal or stress-activated 
protein kinases (JNK/ SAPK) and p38 group of protein kinases (p38) (Su and Karin, 
1996). 
ERKl and ERK2 are two best studied MAPKs which are stimulated by growth 
factors that activate receptor tyrosine kinase activity. There are other isoforms of 
ERKs identified: ERK3, ERK4, ERK5 and ERK7, however, their functions are not 
well characterized. The downstream targets of ERK include transcription factors 
containing E26 transfomation specific (Ets) domain and c-Myc. ERKs respond to a 
variety of growth and differentiation signals (Woessmann and Mivechi, 2001). On the 
other hand, JNK and p38 are involved in more complex tasks. They respond to not 
only hormones and cytokines but also environmental stresses like heat shock and 
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osmotic shock; and thus, these two pathways are usually linked to induction of 
apoptosis (Nagata and Todokoro, 1999). 
JNKs, as their name suggests, they phosphorylate the regulatory sites in the 
N-terminus of the transcription factor c-Jun. There are three isoforms of JNKs - JNKl, 
JNK2 and JNK3. JNK3 expression is restricted to the brain and its presence is related 
to excitotoxicity; while expression of JNKl and JNK2 is not tissue-specific and they 
are activated when exposed to insulin and pro-inflammatory cytokines. JNKs also 
phosphorylate other transcription factors such as activating transcription factor-2 
(ATF-2), c-Jun and p53 and mitochondrial proteins of the Bcl-family (Bogoyevitch et 
al., 2004). 
p38 a (or p38) was first isolated as 38-kDa protein which was rapidly 
phosphorylated after lipopolysaccharide (LPS) treatment. Later, this 38-kDa protein 
was characterized to be a member of the MAPK family. There are three homologues 
of p38 in mammals, p38/3, p38 7 (also known as ERK6 or SAPK3) and p38 6 (also 
known as SAPK4) (Blanco, 2000). Among the four homologues, p38 a and p38 /5 
genes are ubiquitously expressed but expression of p38 7 and p38 d genes are 
tissue-specific: p38 7* in skeletal muscles while p38 6 in lung, kidney, testis, pancreas 
and small intestine. The roles of the three p38 homologues are less clear. Many 
ligands, for examples the erythropoietin, interleukins 2 and 3 and insulin-like growth 
factors (IGF), are able to activate p38 a . Examples of transcription factors activated 
by p38 are activating transcription factor-1 (ATF-1), growth arrest and DNA damage 
inducible gene 153 (GADD153) and serum response factor (SRF) accessory protein 1 
(Sapl) (On and Han, 2000). 
There have been extensive studies on the mechanisms of the fetal hemoglobin 
inducing drugs and most of the findings are related to the MAPK signaling pathway. 
The activity of ERK in 7 -globin induction is dependent on the type of inducing 
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agents. Drugs like hydroxyurea, sodium butyrate (Rivero and Adunyah, 1996; Witt et 
al, 2000) Cyclosporin A (Sawaftiji et al, 2003) and valproate (Witt et al., 2002) 
negatively regulate the activity of ERK; while hemine and cisplatin activate ERK 
during hemoglobin induction (Woessmann et al., 2004). Recently, it has been found 
that overexpression of MEKl in K562 which caused a significant increase in ERK 
phosphorylation silenced the 7 -globin gene expression. The addition of ERK 
inhibitor U0126 augmented 7 -globin gene expression. The data reconciled that the 
blockade of ERK signaling pathway is required for 7 -globin gene induction 
(McElveen et a/., 2005). 
Involvement of JNK during 7 -globin gene reactivation is poorly understood. So 
far, only hydroxyurea demonstrated an increase in mRNA level of c-Jun, accompanied 
by an induction of 7 -globin chain synthesis, upon its administration to K562 
(Adunyah et al., 1995). 
Activation of p38 signaling pathway has been reported in 7 -globin synthesis by 
histone deacetylase inhibitors like sodium butyrate, apicidin (Witt et al., 2003) and 
scriptaid (Johnson et al., 2005), hydroxyurea (Park et al.’ 2001), Cyclosporin A 
(Sawafuji et aL, 2003), valproate (a short chain fatty acid) (Witt et al, 2002). 
Over-expression of MAPKK3 and MAPKK6, which are the immediate upstream 
activators of p38, in K562 showed an increase in 7 -globin mRNA in the absence of 
any HbF inducers (Pace et al., 2003). Thus, p38 activation may be one of the 
pathways which regulate 7 -globin gene expression. 
The objectives of this part of the project were to study the MAPK activity 
modulated by LC978 using Cellular Activation of Signaling ELISA, CASE™ Kit and 




4.2.1 Chemicals and Reagents 
Chemical/ Reagent Source, Catalog Number 
RPMI Medium 1640, powder Gibco 23400-021 
Dulbecco's Phosphate-Buffered Saline (D-PBS), 
, Gibco 21600-010 
powder 
Sodium Bicarbonate (NaHCOs), Cell Culture Tested Sigma S5761 
Fetal Bovine Serum, Qualified Gibco 10270-106 
Antibiotic-Antimycotic (1OOX)，liquid Gibco 15240-062 
LC978, • g / m l 一 一一 ^ ^ 
Hydroxyurea (HU) Sigma H8627 
SB203580 Calbiochem 559389 
Anisomycin, Streptomyces griseolus Calbiochem 176880 
Phorbol 12-myristate 13-acetate (PMA) Sigma P8139 
Dimethyl sulfoxide (DMSO) Sigma D2650 
3 7% Formaldehyde Merck 104003 
Hydrogen Peroxide (H2O2, 30% w/w) BDH 101284N 
Sodium azide (NaNa) Sigma S8032 
Sodium dodecyl sulfate (SDS) Sigma L5750 
Sodium Carbonate (Na2C03) Sigma S7795 
Sodium Bicarbonate (NaHCOs) Sigma S6297 
Trizma® Base, NH2C(CH20H)3 Sigma T6066 
Sodium Chloride (NaCl) RDH 31434 
Tween 20 US 20605 
Bovine Albumin Fraction V Gibco 11018-017 
3，3', 5’ 5'-Tetramethylbenzidine (TMB) Sigma 527A-1KT 
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Dimethyl sulfoxide (DMSO) Sigma D2650 
Sulphuric Acid (H2SO4), 98% Ajax Chemicals 
Triton X-100 Fluka 93426 
0.4% Trypan Blue Solution Sigma T8154 
4.2.2 Kits 
Kit Source, Catalog Number 
Human Fetal Hemoglobin (HbF) ELISA Quantitation Bethyl Laboratories 
Kit E80-136 
Cellular Activation of Signaling ELISA, CASE™ Kit 
forERKl/2,T202/Y204 SuperArray FE-0Q2 
Cellular Activation of Signaling ELISA, CASE™ Kit 
, ^ SuperArray FE-004 
for JNK,T183/Y185 ^ � 
Cellular Activation of Signaling ELISA, CASE™ Kit 
, b SuperArray FE-003 
for p38,T180/Y182 ^ � 
4.2.3 Buffers and Solutions 
Buffer/ Solution Preparation 
1 pack of RPMI Medium 1640 powder and 
2.0g sodium bicarbonate was added to 950ml 
Milli-Q H2O. The pH of the mixture was 
RPMI Medium 1640 乂 ^ 
adjusted with IM NaOH to pH 7.2. Milli-Q 
(2.05mM L-glutamine, 25mM 
H7O was added to make up the medium to IL. 
HEPES Buffer and 0.02M ~ ^ 
The medium was filtered through 0.22Lim filter. 
NaHCOs) 
Complete RPMI was prepared by adding FBS 
and PSF at final concentrations of 10% and 1% 
respectively. 
2X Growth Medium was prepared by adding 
2X Growth Medium FBS and PSF to Complete RPMI at final 
concentrations of 20% and 2% respectively. 
IX PBS (2.67mM KCl, 1.47mM 1 pack of PBS powder was dissolved in IL 
KH2PO4, 137.93mM NaCl and Milli-Q H2O. The solution was autoclaved, 
8.1 OmM Na2HP04) cooled to room temperature and stored at 4°C. 
0.15g HU was dissolved in 3ml PBS and 
50mg/ml Hydroxyurea filtered through 0.22|im filter under sterile 
condition. 
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r , , � … 八 I m g of SB203580 was dissolved in 1ml of 
Img/ml SB203580 m f … ， … � 
DMSO and the drug was stored at -20 C. 
, , . . Img of Anisomycin was dissolved in Iml of 
1 mg/ml Anisomycm , , „ 
DMSO and the drug was stored at 4 C. 
, , Img of PMA was dissolved in 1ml of DMSO 
1 mg/ml PMA f , , � 
and the drug was stored at -20 C. 
, Ig of NaNs was dissolved in 10ml of Milli-Q 
10% NaNs (w/v) 
H2O. 
, Ig of SDS was dissolved in 100ml Milli-Q 
1% SDS (w/v) H : q 
8% Cell Fixing Buffer (for 2.6ml of 37% Formaldehyde was added to IX 
CASE) PBS. The solution was freshly prepared. 
lOX Washing Buffer was diluted to IX with 
1X Washing Buffer (for CASE) ^ 
Milli-Q H2O just before use. 
400|^ 1 of 30% H2O2 and 120LI1 of 10% NaNs 
Quenching Buffer (for CASE) ^ ^ 
were added to 11.48ml of IX Washing Buffer. 
IX Antigen Retrieval Buffer (for lOX Antigen Retrieval Buffer was diluted to IX 
CASE) with Milli-Q H2O just before use. 
The blocking buffer powder was dissolved in 
Blocking Buffer (for CASE) 
30ml of IX Washing Buffer. 
Coating Buffer, 50mM 0.0795g NaaCOs and 0.357g NaHCOs were 
Carbonate-Bicarbonate, pH 9.6 dissolved in 100ml Milli-Q H2O. 
6.057g Tris base and 8.182g NaCl were added 
Tris-Buffered Saline (TBS) 
to 900ml Milli-Q H2O. The pH of the solution 
(50mM Tris and 0.14M NaCl), 
was adjusted with HCl to pH 8.0. Milli-Q H2O 
pH 8.0 
was added to make up the buffer to IL. 
Wash Solution The Wash Buffer was freshly prepared. Tween 
(50mM Tris, 0.14M NaCl and 20 was added to IX TBS at final concentration 
0.05% Tween 20) of 0.05% (v/v). 
Blocking Solution (50mM Tris, BSA was added to IX TBS at final 
0.14M NaCl and 1% BSA) concentration of 1% (w/v). 
Sample/ Conjugate Diluent Tween 20 was added to Blocking Solution at 
(50mM Tris, 0.14M NaCl, 1% final concentration of 0.05% (v/v). 
BSA and 0.05% Tween 20) 
0.03g TMB powder (from the Hemoglobin, 
TMB Stock Solution (for Plasma Kit) was dissolved in 5ml DMSO. The 
ELISA), 6mg/ml solution was light-sensitive and had to be 
protected from light. 
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2.555g Citric acid and 3.095g NaH2P04 were 
TMB Substrate Buffer added to 200ml Milli-Q H2O. The pH of the 
(0.05M citric acid and O.IM solution was adjusted with NaOH to pH 5.5. 
NaH2P04) Milli-Q H2O was added to make up the solution 
to 250ml. 
TMB Substrate Solution This solution was freshly prepared. For 12ml 
(0.05M citric acid, O.IM substrate solution, 200)il of 6mg/ml TMB Stock 
NaH2P04, O.lmg/ml TMB and Solution and 4|il of 30% H2O2 were added to 
0.01% H2O2) 12ml pre-warm TMB Substrate Buffer. 
10.7ml H2SO4 was added slowly to 70ml 
2M Stop Solution Milli-Q H2O. Milli-Q H2O was added to make 
up the solution to 100ml. 
Triton X-100 was added to Milli-Q H2O at a 
20% Triton X-100 
final concentration of 20% (v/v). 
20% Triton X-100 was added to TBS at a final 
Cell Lysis Buffer 
concentration of 1% (v/v). 
4.2.4 Equipment and Other Consumables 
Equipment/ Consumables Source, Catalog Number 
Bench-top centrifuge Eppendorf 5415D 
Hemacytometer Bright-Line 
96 MicroWell™ Plates Nunclon™A, round bottom Nunc 163320 
96 Well Clear Flat Bottom Polystyrene High Bind Coming Costar 9018 
Microplate 
CellBIND® 96 Well Clear Flat Bottom Polystrene Coming Costar 3300 
Microplate 
Microplate Reader System, SpectraMax 250 Molecular Devices 
4.2.5 Maintenance of K562 
The cultures were grown in Complete RPMI and maintained by sub-cultured in fresh 
medium when the cell density reached 2 x 10^  cells/ml. The cultures were incubated 
in 37°C humidified CO2 incubator with 95% air and 5% CO2. 
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4.3 Methods 
4.3.1 Roles of three MAPKs - ERK, JNK and p38 in LC978-mediated y-globin 
gene induction in K562 using CASE™ Kits 
I. Cell Seeding 
Cells growing in the log-phase were used to set up the experiment. For each well, 
40,000 cells (in 100|j.l RPMI) were seeded. K562 cells were collected at 300 x g for 
10 minutes and washed twice with RPMI to remove serum on the cells. The cells were 
resuspended in RPMI to a final density of 4 x 10^  cells/ml. 100|xl of the culture was 
added to each well of the CellBIND® 96 Well Clear Flat Bottom Polystrene 
Microplate. Each assay determination required two sets of cells treated in identical 
fashion. One set of cells was treated with phospho-protein specific antibody and the 
other set of cells was treated with the pan-protein specific antibody. Each 
experimental condition was performed in triplicate. The cells were then incubated in 
37°C CO2 incubator for 24 hours to starve the cells and allow the cells to attach to the 
microplate. 
H. Drug Treatment 
The culture medium was removed by low vacuum suction. The cells were treated with: 
100|Lil of RPMI (as negative control), lOO i^l of RPMI containing 25|ig/ml HU, 100|il 
of RPMI containing 3.125ng/ml LC978 and 100|il of RPMI containing anisomycin or 
PMA (as positive control). 40nM of PMA was used as the simulators of ERK and 
JNK pathways while 200ng/ml of anisomycin for p38. After addition of drug, the cells 
were incubated in 37°C CO2 incubator for 3 hours. 
III. Cell Fixing and Blocking 
After drug treatment, the cells were fixed with 8% Cell Fixing Buffer. lOOjil of 8% 
Cell Fixing Buffer was added to each well. The plate was sealed with a piece of 
parafilm and the lid was placed onto the plate. The plate was incubated at room 
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temperature for 20 minutes. After fixing, the plate could be used right away or the 
stored at 4°C for later use. 
The Cell Fixing Buffer was removed by flipping and tapping the plate gently onto a 
paper towel. The cells were washed twice with 200|il of IX Washing Buffer for 5 
minutes each with rocking. 
100|il of Quenching Buffer was added to each well and the plate was incubated at 
room temperature for 20 minutes. The Quenching Buffer was removed and the cells 
were washed once with 200|il of IX Washing Buffer for 5 minutes with rocking. 
lOOjil of IX Antigen Retrieval Buffer was added to each well. The plate with the lid 
off was placed into a microwave oven. The plate was microwaved at LOW Power for 
3 minutes. The plate was then covered with its lid and cooled to room temperature. 
The Antigen Retrieval Buffer was removed and the cells were washed once with 
200|il of IX Washing Buffer for 5 minutes with rocking. 
100|il of Blocking Buffer was added to each well. The plate was incubated at room 
temperature for 1 hour. 
IV. Incubation with Primary Antibody 
The Blocking Buffer was removed and the cells were washed once with 200|al of IX 
Washing Buffer for 5 minutes with rocking. The anti-phospho-protein specific and the 
anti-pan-protein specific primary antibodies were diluted with the Antibody Dilution 
Buffer at 1:300. SOjil of the diluted antibody was added to each well and the plate was 
incubated at room temperature for 1 hour. 
V. Incubation with Secondary Antibody 
The primary antibodies were removed and the cells were washed twice with 200|il of 
IX Washing Buffer for 5 minutes each with rocking. The secondary antibodies were 
diluted with Antibody Dilution Buffer at 1:20. lOO i^l of the diluted secondary 
antibodies were added to each well and the plate was incubated at room temperature 
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for 1 hour. 
VI. Colorimetric Detection 
The secondary antibodies were removed and the cells were washed twice with 200|li1 
of IX Washing Buffer for 5 minutes each with rocking. The cells were then washed 
once with 200|j,1 of PBS. 100|al of pre-warmed Developing Solution was added to 
each well. The plate was incubated at room temperature and protected from direct 
light. The color development was monitored and stopped when the darkest staining 
well turned medium blue. lOOjxl of Stop Solution was added to stop the reaction. The 
absorbance at 450nm was taken on the Microplate Reader. 
VII. Relative Cell Number Determination 
The assay solution was removed and the cells were washed once with 200^1 of IX 
Washing Buffer for 5 minutes with rocking. Then, the cells were washed once with 
200|j,l of Milli-Q H2O for 5 minutes with rocking. The plate was air-dried at room 
temperature for 5 minutes. lOOjxl of Cell Staining Buffer which binds to cell nuclei 
was added to each well and the plate was incubated at room temperature for 5 minutes. 
The plate was rinsed twice with Milli-Q H2O and the cells were washed twice with 
200|il of Milli-Q H2O for 5 minutes each with rocking. 1% SDS was used to 
solubilize cells and release the dye for subsequent quantification at 595nm where this 
absorbance is proportional to cell number. lOOjil of 1% SDS was added to each well 
and the plate was incubated at room temperature on a rocker for 1 hour. The 
absorbance at 595nm was taken on the Microplate Reader. 
VIII. Data Analysis 
The antibody readings were normalized to the relative cell number by dividing the 
OD450 readings for each well by its OD595 readings. 
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4.3.2 Effect of p38 inhibitor SB203580 on HbF induction 
4.3.2.1 Treatment of K562 with SB203580 
Four experimental conditions were tested: (i) negative control; (ii) 10|j,M SB203580 + 
3.125ng/ml LC978; (iii) lO^M SB203580; and (iv) 3.125ng/ml LC978. Each 
condition was performed in triplicate. Using round-bottom 96-well plate, 50|il of 
20^M SB203580 was added to (ii) and (iii) and 50\i\ of RPMI was added to (i) and (iv) 
K562 cells were collected at 300 x g for 10 minutes and washed twice with RPMI to 
remove serum. The cells were resuspended in RPMI in a final density of 3 x 10^  
cells/ml and 50|j.l of the culture (15,000 cells) was added to each well. The plate was 
incubated in 37°C CO2 incubator for 1 hour. 
6.25ng/ml of LC978 was prepared in 2X Growth Medium. 100|^ 1 of6.25ng/ml LC978 
was added to (ii) and (iv); and lOOjil of 2X Growth Medium was added to (i) and (iii). 
The plate was incubated at 37°C CO2 incubator for four days. 
4.3.2.2 Quantitation of HbF induction 
I. Coating Capture Antibody onto Corning High Bind microplate 
On the third day after induction, Ijil of Capture Antibody (A80-136A) was diluted in 
100|il of Coating Buffer for each well to be coated. The plate was sealed with a piece 
of parafilm to minimize evaporation. The plate was then incubated at 4°C overnight. 
After incubation, the Capture Antibody was removed by flipping the plate over the 
sink and tapping gently on paper towel to drain away excess liquid. The wells were 
washed with 200jj.l of Wash Solution for three times by flipping and tapping. 
II. Blocking 
200|il of Blocking Solution was added to each well and the plate was incubated in 37 
�C for one hour. After incubation, the Blocking Solution was removed and the wells 
were washed with 200|il of Wash Solution for three times. 
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III. Sample Preparation 
Cell viability was evaluated by Trypan Blue method. This was done by mixing 10|j,l of 
cell culture with lOjil of 0.4% Trypan Blue Solution, \0\i\ of this mix was added to 
the chamber of the hemacytometer. Dead cells were stained blue while viable cells 
were left unstained. Viability was calculated as the percentage of viable cells out of 
total number of stained and unstained cells. 
1.5 X 10^  cells were collected from each well and centrifuged at 300 x g for 10 
minutes (25 °C) and the culture medium was removed. The cell pellets were lyzed in 
20jil of Cell Lysis Buffer at 4°C for 30 minutes with intermittent rocking to ensure 
complete lysis. The lysates were centrifuge at 13,200rpm for 10 minutes to pellet the 
debris. 2[l\ of the clear lysate was diluted with 998|j,l of Sample/ Conjugate Diluent. 
100|j.l of diluted lysate was added to each well. 
IV. Standard Preparation 
The Human Hemoglobin Calibrator (RC80-135-4) was serially diluted by 2 folds 
according to the chart below: 
Standard Concentration Sample/ Conjugate 
Step Calibrator RC80-135-4 ^ ^ 
(ng/ml) Diluent 
1 500 2|il 2ml 
2 250 0.4ml from Step 1 0.4ml 
3 125 0.4ml from Step 2 0.4ml 
4 62.5 0.4ml from Step 3 0.4ml 
5 31.25 0.4ml from Step 4 0.4ml 
6 15.63 0.4ml from Step 5 0.4ml 
7 7.81 0.4ml from Step 6 0.4ml 
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After dilution, 0.01% Triton X-100 was added to the diluted standard according to the 
following chart. 
Original Standard Total Volume Amount of 0.01% Final Standard 
Concentration (ng/ml) of Standard Triton X-100 added Concentration (ng/ml) 
500 1.6ml 0.4ml 400 
250 0.4ml 0.1ml 200 
125 0.4ml 0.1ml 100 
62.5 0.4ml 0.1ml 50 
31.25 0.4ml 0.1ml 25 
15 . 63 0.4ml 0.1ml 12.5 
7.81 0.4ml 0.1ml 6.25 
100|il of the above standards (w/ 0.002% Triton X-100) was transferred to assigned 
wells (duplicate for each dilution). The plate was incubated in 37°C for one hour. 
After incubation, samples and standards were removed and the wells were washed 
with 200|il of Wash Solution for five times. 
V. HRP Detection Antibody 
The Sheep anti-Human HbF-HRP conjugate antibody (A80-136P) was diluted at 
1:5000 with Sample/ Conjugate Diluent. 100|j,l of the diluted antibody was added to 
each well. The plate was incubated at 37°C for 90 minutes. After incubation, the 
unbound antibody was removed and the wells were washed with 200|il of Wash 
Solution for five times. 
VI. Enzyme Substrate Reaction 
100|il of TMB Substrate Solution was added to each well. The plate was incubated at 
37°C for 5 to 30 minutes until a medium dark blue color was observed. lOOjil of Stop 
Solution was added to each well to stop the TMB reaction. The plate was read at 
wavelength 450nm with a microplate reader. 
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4.3.3 Statistical Analysis 
For comparison of the means of two or more data groups, one-way ANOVA was 
performed and Tukey's Multiple Comparison Test was applied as the post hoc test. 
Data would be considered as statistical significant when p value is smaller than 0.05. 
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4.4 Results 
4.4.1 Roles of three MAPKs 一 ERK, JNK and p38 in LC978-mediated y-globin 
gene induction in K562 using CASE "^^  Kits 
Microarray analysis revealed the role of MAPK pathway in LC978-mediated 7 
-globin gene induction in K562. However, microarray only reflected the changes in 
the downstream gene expression and signals transduced by the MAPK were by means 
of a protein kinase cascade. Therefore, to substantiate the role of MAPK in 
LC978-mediated 7 -globin gene induction, we had to demonstrate that the kinase 
activity in the cascade was altered. A pathway was activated when the kinase was 
being phosphorylated and a pathway was repressed when the kinase was being 
dephosphorylated. Thus, studying the phosphorylation status of the MAPKs enabled 
us to determine which pathways were activated or repressed when LC978 was added. 
The use of Cellular Activation of Signaling ELISA provided us an easy way to 
study the phosphorylation status of a particular MAPK. The three major MAPK 
pathways were investigated - ERK, JNK and p38. K562 cells were treated with 
3.125ng/ml of LC978, 25|ig/ml of hydroxyurea and 40nM of PMA or 200ng/ml of 
Anisomycin (as positive control) for 3 hours. The cells were then fixed and probed 
with primary antibodies specific for the phosphorylation sites of each kinase. 
Secondary antibodies were added and TMB was used as the chromatogen for signal 
visualization. Absorbance at 450nm was taken and the relative cell number was also 
determined using crystal violet solution. OD450 was normalized to the relative cell 
number. The extent of phosphorylation of a kinase was determined when the amount 
of phosphorylated proteins was normalized to the amount of total proteins. 
The amount of phosphorylated proteins and total proteins of different treatment 
groups were found (Figures 4-1, 4-2 and 4-3). All the treatments did not have a 
profound effect on the amount of total ERK (Figure 4-1)，JNK (Figure 4-2) and p38 
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(Figure 4-3). Statistical analysis using one-way ANOVA did not figure out any 
statistical significant differences in the amount of total ERK, JNK and p38 upon drug 
treatments. Cells treated with PMA or Anisomycin induced a larger amount of 
phosphorylated forms of ERK, JNK and p38. Hydroxyurea and LC978 did not induce 
more phosphorylated ERK (Figure 4-1) and JNK (Figure 4-2). Hydroxyurea and 
LC978 were able to induce phosphorylated p38 (Figure 4-3). However, LC978 was 
able to induce more phosphorylated p38 (Figure 4-3). 
Activity of the MAPK pathways was determined by the ratio of the 
phosphorylated form of MAPK to the total MAPK. The ratios of the two forms of 
proteins upon different treatments were calculated and statistical analysis using 
one-way ANOVA was performed (Figures 4-4, 4-5 and 4-6). PMA and Anisomycin 
were able to activate ERK, JNK and p38. Hydroxyurea did not activate ERK (Figure 
4-4) and JNK (Figure 4-5). Though the ratio of phosphorylated p38 to total p38 after 
hydroxyurea treatment was about 1.6 folds higher than that of the control, such 
change was not considered as statistically significant (Figure 4-6). For LC978-treated 
K652, p38 pathway was activated (Figure 4-6) but no activation of ERK (Figure 4-4) 
and JNK (Figure 4-5) was observed. Thus, p38 pathway was involved in 7 -globin 
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Figure 4-1. The amount of phosphorylated ERK and total ERK (normalized to relative 
cell number) upon treatment of the K562 cells with RPMI, 25|ag/ml of hydroxyurea, 
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Figure 4-2. The amount of phosphorylated JNK and total JNK (normalized to relative 
cell number) upon treatment of the K562 cells with RPMI, 25ng/ml of hydroxyurea, 
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Figure 4-3. The amount of phosphorylated p38 and total p38 (normalized to relative 
cell number) upon treatment of the K562 cells with RPMI, 25|ig/ml of hydroxyurea, 
3.125ng/ml of LC978 and 200ng/ml of Anisomycin for 3 hours. 
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Control HU 978 PMA 
Treatment 
rukey's Multiple Comparison Test Mean Diff. q P value 
Control vs HU -0.05688 1.517 P > 0.05 
Control vs 978 0.003683 0.09821 P > 0.05 
Control vs PMA -0.3069 8.184 P < 0.05 
HU vs 978 0.06056 1.615 P > 0.05 
HU vs PMA -0.2500 6.667 P < 0.05 
978 vs PMA -0.3106 8.282 P < 0.05 
Figure 4-4. Effect of hydroxyurea, LC978 and PMA on relative ERK phosphorylation. 
K562 cells were treated with RPMI, 25^g/ml of hydroxyurea, 3.125ng/ml of LC978 
and 40nM of PMA for 3 hours and phosphorylated ERK and total ERK were 
measured. Ratios of the two forms were calculated and analyzed with one-way 
ANOVA. Tukey's Multiple Comparison Test was applied to determine how the mean 
of each treatment group differed from each other. 
103 
Degree of JNK phosphorylation after 3hr of post-induction 
One-way analysis of variance _ _ 
0 . 6 - P value = 0.0053 mmm | | j j | 
o 
Control HU 978 PMA 
Treatment 
Tukey's Multiple Comparison Test Mean Diff. q P value 
Control vs HU -0.03407 0.8500 P > 0.05 
Control vs 978 -0.06483 1.617 P > 0.05 
Control vs PMA -0.4186 10.44 P < 0.01 
HU vs 978 -0.03076 0.7674 P > 0.05 
HU vs PMA -0.3846 9.594 P < 0.01 
978 vs PMA -0.3538 8.826 P < 0.05 
Figure 4-5. Effect of hydroxyurea, LC978 and anisomycin on relative JNK 
phosphorylation. K562 cells were treated with RPMI, 25|a.g/ml of hydroxyurea, 
3.125ng/ml of LC978 and 40nM of PMA for 3 hours and phosphorylated JNK and 
total JNK were measured. Ratios of the two forms were calculated and analyzed with 
one-way ANOVA. Tukey's Multiple Comparison Test was applied to determine how 
the mean of each treatment group differed from each other. 
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0.9-1 
One-way analysis of variance 
0 8 - — 
p value = 0.0035 wmm mmni 
0.7-
00 0.6- — r -
CO 
5 - 0 .5- ^ ^ m 
0 0 — I — 
w 0.4- Bsssd 國 ^ ^ ^ 
^ 0.3- l l p l I ^ ^ 
0.2- 丨丨丨丨|l 
0.1- | | | 
0-0 ^ ^ ^ ^ ^ ^ IIIIIIIIIIIML 
Control HU 978 Anisomycin 
Treatment 
rukey's Multiple Comparison Test Mean Diff. q P value 
Control vs HU -0.1572 3.817 P > 0.05 
Control vs 978 -0.2809 6.823 P < 0.05 
Control vs Anisomycin -0.5288 12.84 P < 0.01 
HU vs 978 -0.1238 3.006 P > 0.05 
HU vs Anisomycin -0.3716 9.025 P < 0.05 
978 vs Anisomycin -0.2478 6.019 P < 0.05 
Figure 4-6. Effect of hydroxyurea, LC978 and anisomycin on relative p38 
phosphorylation. K562 cells were treated with RPMI, 25|j.g/ml of hydroxyurea, 
3.125ng/ml of LC978 and 200ng/ml of Anisomycin for 3 hours and phosphorylated 
p38 and total p38 were measured. Ratios of the two forms were calculated and 
analyzed with one-way ANOVA. Tukey's Multiple Comparison Test was applied to 
determine how the mean of each treatment group differed from each other. 
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4.4.2 Effect of p38 inhibitor SB203580 on HbF induction 
To confirm the role of p38 pathway in LC978-mediated 7 -globin gene 
induction, specific inhibitor of p38 kinase was used to in the assay and the amount of 
fetal hemoglobin induced by LC978 was measured by HbF ELISA. 
K562 cells were treated as described in section 4.3.2.1 and amount of fetal 
hemoglobin was measured by HbF ELISA. After 4 days of drug treatment, cell 
viability of different treatment groups was evaluated by trypan blue exclusion assay. 
All groups showed viability of more than 99% (Figure 4-7). For each group, 1.5 x 10^  
cells were collected for HbF ELISA. The fetal hemoglobin content of the negative 
control was 206.22ng/ml, SB203580+LC978-treated K562 was 886.38ng/ml, 
SB203580-treated K562 was 13.29ng/ml and LC978-treated K562 was 2453.94ng/ml 
(Figure 4-8). Statistical analysis using one-way ANOVA was performed. Only the 
fetal hemoglobin contents between the control and SB203580-treated K562 did not 
show statistical significance (p>0.05). Comparison of the means of all other pairs did 
have a statistical significance (p<0.001). Treating K562 cells with SB203580 
suppressed the fetal hemoglobin induction by LC978 by 2.7 folds. 
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100 
9 9 T - …一 - - I - - ._ —— . _ 
I 9 7 - — — 丨 丨 I I I 丨丨I - -- … 一 — — _ _ _ — I a Control 
9 6 ：：：：：：：：：：：：： ^ ^ ^ ^ ^ '1;X'I'X'1'1； — 
I 95 |；；；：|； — ^ ^ — — ：：；|：；：：：：：：： ：； Inhibitor 
^ 95 1：；：：：：：：：：|1 ainhibitor+978 
I ：“ iNii--"-" 
93 -——- ： i i r - -- ——————1丨丨丨賴關—— 
9 2 ：：：：：：：：：： --. ^ ^ ^ ^ ^ [||1]|||[1|![1[1| 
Treatments 
Figure 4-7. Cell viability upon treatment with lOjiM of SB203580, \0\iM of 
SB203580 + 3.125ng/ml of LC978 and 3.125ng/ml of LC978 alone. K562 cells were 
treated as described as section 4.3.2.1 and viability was determined by trypan blue 
exclusion assay. 
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Fetal hemoglobin levels of K562 cells treated with inhibitor and LC978 
3000 -1 
One-way analysis of variance 
^ P value < 0.0001 ^ f c 
r： ： I 
/ y 
Treatments 
fukey's Multiple Comparison Test Mean Diff. q P v a l u e~ 
Control vs Inhibitor 192.9 3.636 P > 0.05 
Control vs Inhibitor + 978 -680.2 12.82 P < 0.001 
Control vs 978 -2248 42.36 P < 0.001 
Inhibitor vs Inhibitor + 978 -873.1 16.45 P < 0.001 
Inhibitor vs 978 -2441 45.99 P < 0.001 
Inhibitor+ 978 vs 978 -1568 29.54 P < 0.001 
Figure 4-8. Fetal hemoglobin levels of K562 cells treated with inhibitor 10|iM of 
SB203580 and 3.125ng/ml of LC978. K562 cells were treated as described as section 
4.3.2.1 and fetal hemoglobin levels were measured by Human HbF ELISA. Statistical 
analysis of the fetal hemoglobin levels was performed using one-way ANOVA. 
Tukey's Multiple Comparison Test was applied to determine how the mean of each 
treatment group differed from each other. 
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4.5 Discussions 
4.5.1 Roles of three MAPKs - ERK, JNK and p38 in LC978-mediated y-globin 
gene induction in K562 using CASE "^^  Kits 
To study protein kinase activity, two kinds of kinase assays are commonly used. 
They are the in-gel kinase assay and western blot analysis. In the in-gel kinase assay, 
the kinases are separated by polyacrylamide gel and the gel is renatured in 6M 
guanidine HCl. The renatured polypeptides in the gel are incubated with radioactive 
isotopes like 7 for phosphorylation of either the substrate included in the 
polyacrylamide gel or the kinase itself. Unreacted y -[ P]-ATP is removed and the 
bands of incorporated [^ ^P] phosphate are then visualized by autoradiography 
(Kanieshita and Fujisawa, 1989). While this method is sensitive, it is also 
cumbersome and is not suitable to high-throughput application. 
In Western blot analysis, cells are lysed and total cellular proteins are separated 
by polyacrylamide gel. The separated proteins are transferred to a piece of membrane 
and probed with antibodies that recognize the phosphorylated or pan proteins. 
Although this method is less tedious than in-gel kinase assays, it requires the 
preparation of whole-cell extract and proper handling of the protein extracts to avoid 
degradation. 
The use of Cellular Activation of Signaling ELISA (CASE™) Kits provide an 
efficient kinase assay method which eliminates the need of cell lysis, electrophoresis 
and using radioactive substances. This method works in a 96-well format and 
quantitation of phosphorylated proteins, total proteins and cell number can be 
achieved at one time. 
Both LC978 and hydroxyurea did not activate ERK and JNK but did activate p38 
pathway. Pace et al. demonstrated the role of p38 kinase in regulating 7 -globin gene 
expression in K562. Over-expression of MAPKK3 and MAPKK6, which are the 
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immediate upstream activators of p38, in K562 showed an increase in y -globin 
mRNA in the absence of any HbF inducers (Pace et al, 2003). Our findings on LC978 
also supported that y -globin gene induction through p38 pathway. 
The findings on hydroxyurea were a bit different from expectations. Previous 
findings on y -globin gene induction by hydroxyurea demonstrated the repression of 
ERK was involved in y -globin gene induction (Park et al., 2001). However, our data 
showed that there was neither activation nor repression of ERK when K562 cells were 
treated with hydroxyurea. A possible explanation for such deviation was due to the 
difference in the experimental conditions. ERK activity was detected by Western blot 
analysis in which cells were grown in normal condition and hydroxyurea was added. 
Cellular proteins were extracted at different time points and ERK activity was 
determined by Western blot. It was found that treatment with hydroxyurea reduced the 
phosphorylation of ERK. On the other hand, our experiment on ERK activity was 
performed in serum-free condition and cells were starved beforehand. Since serum 
contains a variety of growth factors which are the stimulators of MAPK pathway, 
cells were starved to minimize the background activity of MAPK. However, ERK is 
involved in cell growth and proliferation and if the cells were starved to arrest cell 
growth, ERK activity would be reduced. So we expected that the basal ERK activity 
in starved cells would be low. Ajenjo et al had shown that ERK activity only varied 
very slightly between growing and starved K562 cells (Ajenjo et al, 2000). Thus, a 
drop in ERK activity should be detected no matter the cells were grown in culture 
medium with serum or without serum. 
Our results showed there was neither activation nor suppression of ERK activity 
in K562 induced with hydroxyurea; and two possibilities were raised. First, was the 
CASE Kit not sensitive enough to detect the down-regulation of phosphorylated ERK 
in starved cells? Second, was the mechanism of hydroxyurea in inducing hemoglobin 
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in starved cells different from that in growing cells? 
To check whether the CASE Kit could detect the down-regulation of 
phosphorylated ERK in starved cells, starved K562 cells were treated with MEK 
inhibitor U0126 and ERK activity was measured by CASE Kit. MEK is the upstream 
activator of ERK. It was found that the down-regulation of the level of 
phosphorylated ERK brought by U0126 could be detected by the CASE Kit (See 
Appendix, Figures A-1 and A-2). Thus, the first possibility could be ruled out. 
The second concern would focus on the action of hydroxyurea. Ajenjo et al. 
demonstrated that there was no change in ERK activity in starved K562 cells induced 
by hydroxyurea (Ajenjo et al, 2000) while Park et al. illustrated inhibition of ERK 
activity in growing K562 cells induced by hydroxyurea (Park et al., 2001). 
Hydroxyurea is a HbF inducer and also a ribonucleotide reductase inhibitor which 
inhibits DNA synthesis and causes cell cycle arrest (Elford, 1968). It might be 
possible that cell growth inhibition was one of the processes accompanying the 
hemoglobin induction in K562. Therefore, in starved cells where growth had been 
repressed, hemoglobin induction by hydroxyurea could go straight ahead without the 
need to turn down cellular proliferation via ERK pathway and that's why no inhibition 
of ERK activity was observed in our experiment. To validate this hypothesis, the 
experiment could be repeated together with a set of cells grown in normal condition 
and treated in an identical fashion as the starved cells. 
Another discrepancy was discovered while interpreting data from p38. 
Hydroxyurea was found to activate p38 pathway (Park et al., 2001) but our data did 
not have a statistical significant difference in the ratios of the phosphorylated p38 to 
total p38 in hydroxyurea-treated K562 and that in untreated K562. This might be due 
to the inappropriate timing for observing the maximal activation of p38 pathway. In 
Park's work, p38 was phosphorylated slightly 4 hours after hydroxyurea addition and 
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phosphorylated p38 further increased and peaked at 24 hours and sustained for 4 days. 
Thus, the level of phosphorylated p38 in our experiment might increase if the 
treatment time increased beyond 3 hours. 
Role of JNK in 7 -globin gene regulation was poorly understood. In mouse 
erythroleukemia cells, erythropoietin activated JNK and in turn led to erythroid 
differentiation (Nagata et al, 1998, 1999). However, the data from Park et al. showed 
that hydroxyurea suppressed the phosphorylation of JNK (Park et al, 2001). No 
further work, for examples using JNK inhibitor or over-expression of JNK mutant, to 
clarify the role of JNK in 7 -globin gene regulation had been done. So, it was not 
sure that whether our data on JNK was also resulted from disparity in experimental 
condition as the case of ERK or other unknown reasons. 
4.5.2 Effect of p38 inhibitor SB203580 on HbF induction 
Since LC978 activated p38 kinase, inhibitor of p38 kinase, SB203580, was 
applied to test whether blocking of p38 pathway would also reduce fetal hemoglobin 
induction by LC978. 
SB203580 is a pyrindinyl imidazole which inhibits p38 specifically and fails to 
affect the activity of JNK and ERK. When it is used at lO i^M, it can inhibit 99% of 
p38 activity while attaining a very low inhibitory effect on other MAPK (Davies et al, 
2000). SB203580 binds to the ATP binding site of p38 kinase and thus preventing 
phosphorylation of downstream targets but not preventing phosphorylation of p38 
kinase by its upstream activators, MKK3 and MKK6 (Cuenda et al., 1995). 
The treatment of K562 cells with lO^M of SB203580 for 4 days did not fully 
suppress the fetal hemoglobin induction by LC978. Even SB203580 was added, 
LC978 would still be able to induce fetal hemoglobin at a level 4 folds more than the 
untreated control, though it was still 2.7 folds less than the fetal hemoglobin induced 
in treating cells with LC978 alone. The hemoglobin-inducing ability of LC978 
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overrode the inhibitory action of SB203580. This would be possibly due to the effect 
of SB203580 was diluted when the cell grew and SB203580 was being degraded 
making the proportion of cells receiving SB203580 was much smaller than that 
responsive to LC978. However, shortening the assay time to two or three days in 
order to investigate whether SB203580 could completely abolished the 
hemoglobin-inducing effect of LC978 would not be feasible because LC978 did not 
induce a significant amount of fetal hemoglobin until four days of induction. If 
long-term effect of SB203580, for example after seven days of induction, had to be 
studied, replenishing the culture medium with inhibitor would be a solution. 
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Chapter 5 Summary And Prospects 
The discovery of LC978 from Trichosanthes kirilowii Maxim shed light on the 
gene switch therapy to cure -thalassemia. LC978 was shown to be more efficacious 
and reliable than the currently used drug hydroxyurea. LC978 induced fetal 
hemoglobin production in human erythroleukemia cell line K562 as evidenced in 
RT-PCR using 7 -globin gene specific primer and fetal hemoglobin ELISA. 
Understanding the molecular mechanism of how LC978 induced fetal 
hemoglobin would allow us to determine its mode of action and hopeful to dig out 
compounds that could act synergistically with it. To start looking for possible signal 
transduction pathways modulated by LC978, we first had to screen as many pathways 
as possible. Oligonucleotide-based microarray was chosen as the screening tool and 
not surprisingly, MAPK was involved as in many other fetal hemoglobin inducing 
drugs. 
Further investigation on how the three major MAPK pathways, namely ERK, 
JNK and p38, were regulated was performed by cell-based ELISA. Both LC978 and 
hydroxyurea modulated the three MAPK pathways in a manner where no change in 
the activity of ERK and JNK was observed while p38 was activated. Park et al 
demonstrated the repression of ERK was involved in 7 -globin gene induction by 
hydroxyurea (Park et al.’ 2001). A possible explanation for such deviation was due to 
the difference in the experimental conditions. ERK activity was detected by Western 
blot analysis in which cells were grown in normal condition and hydroxyurea was 
added. Cellular proteins were extracted at different time points and ERK activity was 
determined by Western blot. It was found that treatment with hydroxyurea reduced the 
phosphorylation of ERK. On the other hand, our experiment on ERK activity was 
performed in serum-free condition and cells were starved beforehand. Basal ERK 
activity would be low in starved cells and we questioned the sensitivity of the CASE 
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Kit and mechanism of hydroxyurea in inducing hemoglobin in starved cells and in 
growing cells. 
The sensitivity of the CASE Kit was clarified by treating the starved K562 cells 
with MEK inhibitor U0126. It was proved that even the cellular ERK activity was low 
in starved K562 cells, the CASE Kit was able to measure further drop in ERK activity 
after treatment with U0126. 
The second concern would focus on the action of hydroxyurea. Ajenjo et al 
demonstrated that there was no change in ERK activity in starved K562 cells induced 
by hydroxyurea (Ajenjo et al, 2000) while Park et al. illustrated inhibition of ERK 
activity in growing K562 cells induced by hydroxyurea (Park et al, 2001). 
Hydroxyurea is a HbF inducer and also a ribonucleotide reductase inhibitor which 
inhibits DNA synthesis and causes cell cycle arrest (Elford, 1968). It might be 
possible that cell growth inhibition was one of the processes accompanying the 
hemoglobin induction in K562. Therefore, in starved cells where growth had been 
repressed, hemoglobin induction by hydroxyurea could go straight ahead without the 
need to turn down cellular proliferation via ERK pathway and that's why no inhibition 
of ERK activity was observed in our experiment. 
Pace et al demonstrated that over-expression of MAPKK3 and MAPKK6, which 
are the immediate upstream activators of p38, in K562 showed an increase in 
7 -globin mRNA in the absence of any HbF inducers (Pace et al., 2003). Our findings 
on LC978 also supported that 7 -globin gene induction through p38 pathway. 
Application of p38-specific inhibitor SB203580 suppressed the fetal hemoglobin 
induction. These results demonstrated again LC978, like hydroxyurea and butyrate, 
induced fetal hemoglobin via p38 pathway. 
Though p38 was involved in LC978 action, we did not have any information on 
its activity across the 7-day LC978 induction profile. A time-course study of p38 
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activity and y -globin gene induction by LC978 would allow us to better understand 
the role of p38. We could measure p38 activity not only after hours of post-induction 
but also after days of post-induction in order to determine whether a transient or a 
sustained p38 activation was required for LC978-mediated 7 -globin gene induction. 
At the moment, we only know that p38 kinase was activated by LC978 but we 
had no information on which transcription factors are responsible for regulating the 
7 -globin expression. Follow-up study highlighting the interaction of downstream p38 
effectors and 7 -globin gene promoter will be highly recommended. Recently, a 
research group have identified a consensus ATF-2/ CREB motif in the ^ 7 -globin 
promoter. This site was able to bind the two p38 effectors，ATF-2 and 
cAMP-Responsive Element Binding (CREB) Protein, in vivo (Pace et al., 2006). 
There are other p38 downstream effectors which may be the candidate regulators of 
7 -globin gene. For examples, the MAPK-activated protein kinases (MAPKAPK) 1 
and 2 (Hazzalin et al., 1996), p38-regulated/activated protein kinase (PRAK) (New et 
al., 1998)，ATF-1-4 (Ono and Han, 2000) and cAMP-Responsive Element Modulator 
(CREM) (Foulkes et al, 1991) can be potential regulators. Electromobility gel shift 
assay (Gamer and Revzin, 1981) can first be employed to explore proteins that bind to 
the 7 -globin gene promoter. Proteins that bind to the promoter can be extracted, 
purified and identified by MALDI-TOF (Dauly et al, 2006). Functional roles of these 
transcription factors in modulating 7 -globin gene expression can be elucidated by 
construction of a knockout mice or over-expression of the transcription factors. 
This project only focused on fetal hemoglobin induction and MAPK pathway 
and indeed other signaling pathways could be studied using a more sophisticated 
microarray platform such as the Affymetrix Human Genome Array to obtain a more 
complete picture of signal transduction pathway regulation. The current awareness on 
signal transduction studies highlights the cross-talk between different pathways as 
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most of the methods used only detect the signal transduction components in the 
mid-stream of the pathways; and activation or repression of the pathways may be 
altered by components of other pathways upstream. Identifying signaling pathways 
cross-acting with MAPK will help us to better understand fetal hemoglobin 
reactivation and the effect of LC978 on K562. 
At the moment, we only know that p38 kinase was activated by LC978 but there 
are many other transcription factors responsible for regulating the 7 -globin 
expression. These transcription factors may be interacting with each other and 
forming complex which binds onto the 7 -globin gene promoter, for example the 
interaction of CP2 and NF-E4 (Zhou et al., 2000). Resolving the intricate picture of 
DNA-protein and protein-protein interactions on the 7 -globin gene promoter 
certainly allows us to better understand the hemoglobin switching event. 
Receptors conveying signals via p38 pathway are myriad, for examples the TGF-
/3 receptor (Funaba et al., 2006) and EPO receptor (Nagata et al, 1997). It will be 
valuable to find out if LC978 will bind to these known receptors or to a novel receptor. 
Knowing the receptor of LC978 enables us to modify its structure and improving its 
efficacy to achieving maximal therapeutic effect on thalassemia patients although the 
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Figure A-1. The amount of phosphorylated ERK and total ERK (normalized to 
relative cell number) upon treatment of the K562 cells with RPMI and 5\iM of MEK 
inhibitor U0126 for 3 hours. ERK activity was measured by CASE Kit as described in 
section 4.3.1. 
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Degree of ERK phosphorylation 
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• P value = 0.0054 
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Figure A-2. Effect of U0126 on relative ERK phosphorylation. K562 cells were 
treated with RPMI and 5|iM of MEK inhibitor U0126 for 3 hours and phosphorylated 
ERK and total ERK were measured by CASE Kit as described in section 4.3.1. Ratios 
of the two forms were calculated and analyzed with paired t-test. 
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